68 Ga-DOTANOC and 18 F-FDG PET/CT in metastatic medullary thyroid carcinoma: novel correlations with tumoral biomarkers

Abstract

Objective

Metastatic disease is common in medullary thyroid carcinoma (MTC) and it is usually detected by raising calcitonin and carcinoembryonic antigen (CEA) levels. Nuclear medicine imaging has an important role in lesion identification/characterisation. We aim to compare ⁶⁸Ga-DOTANOC PET/CT and ¹⁸F-FDG PET/CT performance and to explore the correlations between tumoral markers and functional imaging.

Methods

This a retrospective cross-sectional study including 13 patients with MTC and high calcitonin/CEA levels that underwent both ⁶⁸Ga-DOTANOC PET/CT and ¹⁸F-FDG PET/CT.

Results

⁶⁸Ga-DOTANOC PET/CT identified MTC metastases in 2twopatients that were ¹⁸F-FDG-negative (sensitivity of 69.2% vs. 53.9%, respectively). ⁶⁸Ga-DOTANOC PET/CT also detected a higher number of lesions than ¹⁸F-FDG PET/CT in seven patients, with only one patient showing the opposite pattern. Both differences lacked statistical significance (p = 0.50 and p = 0.86, respectively) but ⁶⁸Ga-DOTANOC PET/CT better performance allowed changes in patients' management. ⁶⁸Ga-positive/¹⁸F-FDG-negative patients were the ones with the lowest calcitonin doubling time and presented a CEA doubling time >24 months, while the patient with more ¹⁸F-FDG-positive lesions was the one with the highest CEA/calcitonin ratio. The number of lesions found in ⁶⁸Ga-DOTANOC PET/CT were correlated with calcitonin levels (r = 0.73; p < 0.01) but not with CEA ones (r = 0.42; p = 0.15). The number of ¹⁸F-FDG hypermetabolic focus were correlated with CEA levels (r = 0.60; p < 0.05) but not with calcitonin (r = 0.48; p = 0.09).

Conclusions

This is the first study to describe a positive correlation between ⁶⁸Ga-positive lesions and calcitonin levels and between ¹⁸F-FDG-positivity and CEA levels. Tumoral markers pattern in metastatic MTC could help clinicians to decide which exam to perform first.

http://bit.ly/2sKzxeN

Correction to: Factors predicting long-term comorbidities in patients with Cushing’s syndrome in remission

The original version of this article unfortunately published with traditional Springer copyright instead of open access under Springer compact agreement.

http://bit.ly/2FSVrnT

The long-term prognosis of heart diseases for different metabolic phenotypes: a systematic review and meta-analysis of prospective cohort studies

Abstract

Purpose

This meta-analysis aimed to assess the association of different categories of weight and metabolic status with risk of heart diseases including myocardial infarction (MI), cardiovascular diseases (CVDs), and heart failure (HF).

Methods

Data from relevant studies were identified systematically by searching PubMed and Scopus search engines up to 29 May 2018. Prospective studies were included in the analyses with metabolically healthy normal weight (MHNW) as the reference. Pooled RRs and 95% CI were calculated using random-effects or fixed-effect models when appropriate. Subgroup analysis was applied to define possible sources of heterogeneity.

Results

Overall, 21 studies (n = 778,401 participants) were eligible for the present meta-analysis. Generally, the risk of CVDs for all metabolic phenotypes in metabolically unhealthy obese increased compared with the MHNW group. A significant positive association between all metabolic phenotypes and the risk of HF was also observed expect for MHOW (RR = 1.10, 95% CI: 0.60–2.00, P = 0.76) and MHO phenotypes (RR = 0.96, 95% CI: 0.25–3.77, P = 0.95). Moreover, MUHO phenotype was associated with greater risk of MI compared with the MHNW phenotype (RR = 1.82, 95% CI: 1.50–2.22, P < 0.001, respectively).

Conclusions

Our findings showed that all metabolically unhealthy phenotypes in different categories of weight were associated with increased incident of CVDs/HF and MI. Furthermore, healthy overweight and obese subjects had increased risk of CVDs.

http://bit.ly/2RFj9Lk

Einseitige schmerzhafte Schwellung der Leiste nach ungeschütztem Geschlechtsverkehr

http://bit.ly/2HyjI4V

Raynaud-Phänomen

Zusammenfassung

Das Raynaud-Phänomen (RP) ist eine häufige akrale Durchblutungsstörung bei der es durch eine pathologische Kontraktion kleiner arterieller Gefäße zu einem schmerzhaften Abblassen einzelner Akren (am häufigsten der Finger) kommt. Bei dem häufigen sog. primären RP liegt lediglich eine funktionelle Störung des Gefäßtonus vor, beim seltenen sekundären RP kommen zusätzlich strukturelle Änderungen im Bereich der Gefäße hinzu. Die Kenntnis dieser Erkrankung ist für den Dermatologen wichtig, da das sekundäre RP mit dem Vorliegen oder der Entwicklung schwerwiegender Grunderkrankungen, insbesondere einer systemischen Sklerose, assoziiert sein kann. Das diagnostische Vorgehen sowie die wichtigsten therapeutischen Ansätze werden in diesem Überblick zusammengefasst.

http://bit.ly/2SbT2v4

Neural Switch Asymmetry in Feature-Based Auditory Attention Tasks

Abstract

Active listening involves dynamically switching attention between competing talkers and is essential to following conversations in everyday environments. Previous investigations in human listeners have examined the neural mechanisms that support switching auditory attention within the acoustic featural cues of pitch and auditory space. Here, we explored the cortical circuitry underlying endogenous switching of auditory attention between pitch and spatial cues necessary to discern target from masker words. Because these tasks are of unequal difficulty, we expected an asymmetry in behavioral switch costs for hard-to-easy versus easy-to-hard switches, mirroring prior evidence from vision-based cognitive task-switching paradigms. We investigated the neural correlates of this behavioral switch asymmetry and associated cognitive control operations in the present auditory paradigm. Behaviorally, we observed no switch-cost asymmetry, i.e., no performance difference for switching from the more difficult attend-pitch to the easier attend-space condition (P→S) versus switching from easy-to-hard (S→P). However, left lateral prefrontal cortex activity, correlated with improved performance, was observed during a silent gap period when listeners switched attention from P→S, relative to switching within pitch cues. No such differential activity was seen for the analogous easy-to-hard switch. We hypothesize that this neural switch asymmetry reflects proactive cognitive control mechanisms that successfully reconfigured neurally-specified task parameters and resolved competition from other such "task sets," thereby obviating the expected behavioral switch-cost asymmetry. The neural switch activity observed was generally consistent with that seen in cognitive paradigms, suggesting that established cognitive models of attention switching may be productively applied to better understand similar processes in audition.

http://bit.ly/2R90hiL

Kimura’s Disease: A Diagnostic and Therapeutic Challenge

Abstract

Kimura's disease, also known as Eosinophilic Granuloma, is a rare chronic condition seen mainly in Oriental population. It presents with subcutaneous nodules, lymphadenopathy, salivary gland hypertrophy with peripheral eosinophilia and raised serum IgE levels; rarely renal involvement may also be present. Its etiology mainly remains unknown. We present a case series of two patients. Our first case is a middle aged female which presented with a parotid swelling, mimicking a parotid neoplasm. Further investigations revealed associated intra-parotid and cervical lymphadenopathy. An excisional biopsy in the form of Superficial Parotidectomy with lymph node excision was done. Histopathological examination of the excised specimen revealed it to be a case of Kimura's disease. Our second case, a young adult, presented with a gradually increasing post-auricular swelling. Preliminary investigations in this case pointed towards Kimura's disease. Excision biopsy of the lesion was done. Histopathological studies confirmed the diagnosis for the same. Both the patients are under our regular follow up and remain disease-free at a follow up of 1 year and 8 months respectively.

http://bit.ly/2HqWP3e

An Immunohistochemical Study of HIF-1 Alpha in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma

Abstract

To evaluate and compare the expression of HIF-1 Alpha (HIF-1α) in oral epithelial dysplasia (OED) and various grades of Oral squamous cell carcinoma (OSCC). 30 cases each of OEDand OSCC were stained with HIF-1α antibody. Quantification of HIF-1α positive cellswas carried out and the data was statistically analysed. The mean % HIF-1α labeling index (HIF-1α LI) increased significantly from mild OED (32.11%), moderate OED (55.07%), to severe OED (64.58%). There was a statistically significant increase in the expression of HIF-1α as grades of OED increased. The mean HIF-1α LI % in well differentiated OSCC was 46.3%, Moderately differentiated OSCC—76.31% and Poorly differentiated OSCC—89.9%. The mean HIF-1α LI was found to increase with increasing grades of OSCC which was statistically significant (P < 0.05). Further a comparison of mean HIF-1α LI in OED with different histologic grades of OSCC by Independent samples t test was performed. We found statistically significant difference between OED and moderately differentiated OSCC and OED and poorly differentiated OSCC (P = 0.000). Progressive increase in expression of HIF-1α was noted from OED to OSCC. It can be postulated that epithelial dysplastic lesions with increased HIF-1α expression are at greater risk of malignant transformation, suggesting that the expression of HIF-1α is an early event in oral carcinogenesis.

http://bit.ly/2S4Uq2r

To Be Cautious or Not: Tension Pneumothorax After First Tracheostomy Tube Exchange

Abstract

Tracheostomy tube change is a relatively common procedure once a tracheo-cutaneous tract matures. Regular tracheostomy tube changes prevent the formation of granulation tissue and reduce bacterial colonization (Yaremchuk and Yaremchuk in Laryngoscope 113(1):1–10, 2003). However, serious complications such as subcutaneous emphysema, loss of airway and mediastinitis, can occur if the tube exchange is performed inappropriately. We present a rare association of tension pneumothorax following a tracheostomy tube exchange in a 50-year-old patient who underwent tracheotomy 3 days back. The patient was successfully managed conservatively with chest tube and supportive care.

http://bit.ly/2RWz3R1

Evaluation of Quality of Life and Pattern of Improvement of Bronchial Asthma in Chronic Rhinosinusitis Patients Treated by Functional Endoscopic Sinus Surgery

Abstract

Chronic inflammatory disorders of the upper airways are extremely prevalent and have a major impact on public health. Sinusitis and bronchial asthma are closely interrelated diseases and sinusitis is known to influence bronchial asthma in its severity and chronicity. Causal relationships have been proposed but not yet proved. The relationship between sinusitis and asthma is academically interesting and has important diagnostic and therapeutic implications. The present study is designed to evaluate the efficacy of functional endoscopic sinus surgery done as treatment for chronic rhinosinusitis on bronchial asthma patients, in terms of quality of life and pattern of improvement. Objectives of the study were to determine whether bronchial asthma and quality of life improved after functional endoscopic sinus surgery. This was an open labelled randomised control trial, done at ENT Department of Medical College, Thiruvananthapuram. Those in Group A underwent functional endoscopic sinus surgery and group B patients were given only medicines as per standard protocol. All of them received asthma treatment depending on asthma attacks and severity and followed up at specific intervals. Quality of life status and pattern of improvement of bronchial asthma among these patients were evaluated. Patients of chronic rhinosinusitis treated by functional endoscopic sinus surgery showed significant improvement in the mean asthma symptom score, asthma medication use score, pulmonary function test results, and quality of life assessment scores. Functional endoscopic sinus surgery could be considered early in the natural course of chronic rhinosinusitis with concomitant bronchial asthma.

http://bit.ly/2FHHo58

Leiomyosarcoma of Mandible: A Diagnostic Dilemma; Case Report and Review of Literature

Abstract

Leiomyosarcoma and its pleomorphic variant are rare entities in the head and neck region. Since they usually present as slow growing, discrete firm, and non-ulcerated painless mass, they seem to be deceptively benign and are thus misdiagnosed. Histopathological and immunohistochemical studies are the ways of getting a definitive diagnosis. Till date surgery has been the primary treatment but effectiveness of radiotherapy/chemotherapy is still questionable. Here, we describe a case of leiomyosarcoma in mandible along with discussion about the ways of diagnosis, its differentiation with its pleomorphic variant and their managements.

http://bit.ly/2CxPUQ7

Complications of Paediatric Cochlear Implantation in the Population of Uttarakhand

Abstract

Cochlear implants surgery is now routinely done at this center. Complications which have been experienced in cochlear implant surgery at our center are discussed, as a detailed knowledge about the complications and their early anticipation can save an expensive device and most importantly patients morbidity. To discuss the complications of the paediatric cochlear implantation in the population of Uttarakhand. The total of 60 patients were included in this study (age group 1–5 years) who had undergone the cochlear implantation surgery between Sept. 2015 and Sept. 2016. These patients were regularly monitored and followed up for 1 year. All the surgeries were performed by same team of surgeons. Rate of minor complications is 8.33% (reversible facial nerve paresis, injury to chorda tympani nerve, local skin reaction, perilymph gussher) and major complications is 5% (implant rejection and flap necrosis). The various complications should be closely monitored by the surgeon so that these can be avoided.

http://bit.ly/2RDtXd5

Suitable Alternative for Human Cadaver Temporal Bone Dissection: Comparative Micro Ear Anatomy of Cattle, Pig and Sheep with Human

Abstract

The study was undertaken to compare the micro ear anatomy of three commonly available animal models which are expected to have similar anatomy to human and to find out suitable model among them as an alternative for human cadaver temporal bone dissection. This is an observational study of comparison of micro ear anatomy of the three animal models with human. Decapitated heads of cattle, pig and sheep were collected from slaughter houses, soft tissues along with brain were removed and preserved in commercially available formalin preservative. CT scan was taken for the three specimens and 3D reconstructions were done. Each specimen was subjected to micro dissection and the anatomical features were studied and compared with human. Among the three animal models sheep is found to be an ideal model for a beginner because of ease of exposure of bone, very thin cortical bone, and no cellularity, good exposure of all the middle ear structures and similar interrelations of middle ear structures with human. Pig may not be an ideal model because of abundant fatty soft tissues, thick periosteum very narrow space occupied by the middle ear, difficulty in accessing cellularity small fragile ossicular chain and overhanging facial nerve.

http://bit.ly/2FMC6ES

A Study on Deep Neck Space Infections

Abstract

Deep neck space infections (DNSI) are serious diseases that involve several spaces in the neck. These are commonly seen in low socioeconomic group with poor oral hygiene, and nutritional disorders. These are bacterial infections originating from the upper aerodigestive tract. The incidence of this disease was relatively high before the advent of antibiotics. Treatment of DNSI includes antibiotic therapy, airway management and surgical intervention. Management of DNSI is traditionally based on prompt surgical drainage of the abscess followed by antibiotics or nonsurgical treatment using appropriate antibiotics in the case of cellulitis. This study was conducted to investigate the age and gender, clinical symptoms, site involved, etiology, co-morbidities, bacteriology, complications and outcomes in the patients of DNSI. A prospective study of deep neck space infections was conducted during the period July 2017 to July 2018 on the patients who attended the outpatient department and were admitted as inpatient in Safdarjung hospital, New Delhi. 40 Cases with DNSI all ages and both genders were included in the study. Patients who didn't require surgical intervention to drain pus were excluded. All parameters including age, gender, co-morbidities, presentation, site, bacteriology, complications, and investigations were studied. Due to advent of antibiotics, deep neck space infections are in decreasing trend. The common age group found to be affected is in 2nd and 3rd decade in our study. Out of all deep neck space infections, submandibular space infections were common (37.5%) followed by peritonsillar infections (12.5%). Infection of deep neck space remains fairly common and challenging disease for clinicians. Prompt recognition and treatment of DNSI are essential for an improved prognosis. Odontogenic and tonsillopharyngitis are the commonest cause. Key elements for improved results are the prompt recognition and early intervention. Special attention is required to high-risk groups such as diabetics, the elderly and patients with underlying systemic diseases as the condition may progress to life-threatening complications.

http://bit.ly/2FFiwLh

Teaching Ear Examination Skill to Undergraduate Students Using Check List

Abstract

For examination of ear, proper illumination is a pre requisite. Diseases related to ear may lead to altered sense of hearing and may affect normal balance system. If students are taught to examine ear using a check list, they may perform better. To teach ear examination to undergraduate students using a check list. Total 50 undergraduate students of M.B.B.S. attending E.N.T. clinic in Chirayu Medical College and Hospital were included in the study. They were given enrolment no. 1 to 50 and were divided into two groups. Group 1, enroll. no. 1 to 25 and group 2, enroll. no. 26 to 50. Group 1 was taught using check list and the Group 2 was taught without use of checklist. Both the groups were evaluated using check list. The group B students were again taught, using check list and were again evaluated using check list. Use of check list showed that there was statistically significant improvement in learning by students using check list in group 1 students compared to group 2 students who were taught without use of check list. The group 2 students also had improvement on evaluation, after they were taught using check list. Study suggests that use of check list for ear examination skill to undergraduate students has significant role and students learn better than when taught without use of checklist. Inclusion of checklist for teaching ear examination to undergraduate students may be considered.

http://bit.ly/2FLzHKp

Early Intratympanic Methylprednisolone in Sudden SNHL: A Frequency-wise Analysis

Abstract

Sudden sensorineural hearing loss is a dire medical emergency which must be treated at the earliest to get better long term hearing results. Our study aims to determine the efficacy of intratympanic steroid (Methylprednisolone) on auditory outcomes in patients of sudden sensorineural hearing loss and study the relation between time of onset of hearing loss to start of therapy and frequency-wise recovery of hearing loss. A prospective cohort clinical study with 33 patients with sudden hearing loss of 30 dB or more were treated with the intratympanic injection of methylprednisolone and the effect of the drug was observed. In this study, 33 patients with sudden onset (unilateral or bilateral) of hearing loss were treated with intratympanic methylprednisolone. The duration at which the drug was administered and the age of the participants was taken into consideration. Main outcome measures included audiometry results at low, medium and high hearing loss frequencies. The specific frequency at which the hearing improvement took place was tabulated. It was observed that hearing improved significantly if the steroid is injected within the first 4 days of onset (p < 0.05) at all the frequencies. A gain of 15 dB or more was achieved in more than 78% patients after injecting methylprednisolone intratympanically. A statistically significant association was found between recovery rate and frequency of hearing loss with patients showing greater improvement at low hearing loss frequency in comparison to mid and high frequencies (p < 0.05). The drug efficacy does not change with the age of the patient.

http://bit.ly/2RVKxnH

Reconstructive Ladder for Transoral Resections of Oropharyngeal Cancers

Abstract

Purpose of Review

Transoral robotic surgery (TORS) now offers extended reach and capability to the head and neck oncologic surgeon, but in doing so, provides a reconstructive dilemma. The objective of this manuscript is to discuss the most recent advances and options available after resection with TORS.

Recent Findings

The latest research provides a common framework for surgeons to classify the type of oropharyngeal defect. A variety of reconstructive options described include secondary intent, modifications to existing local and regional flaps, and advances utilizing robotic assistance in free flap reconstruction.

Summary

There exists a multitude of reconstructive options with appropriate considerations for a stepwise approach based on patient-specific factors, surgeon capability, and the extent of the oropharyngeal defect. Just as robotic resection extends the capability in extirpation, it is now being used to refine free flap inset in the appropriate case.

http://bit.ly/2G0G0tU

Technical Challenges in Temporal Bone Paraganglioma Surgery: a Clinical Review

Abstract

Purpose of the Review

Temporal bone paragangliomas have always presented the otologist with their ultimate challenge. Surgical management is difficult, dangerous and demanding. It is also often associated with increased cranial nerve deficits and decreased quality of life for the patient. Management protocols for patients with temporal bone paragangliomas are changing as a result of advances in knowledge and technical developments. Multi-disciplinary care is now recommended for most patients with surgical intervention becoming restricted for the most difficult tumours.

Recent Findings

Previously considered unresponsive or resistant to radiotherapy, recent experiences using stereotactic radiosurgery techniques suggest that this is not correct. Tumour growth can be halted in some and slowed down in others. Advances in molecular medicine have defined a number of paraganglioma predisposition syndromes. Recognition of these syndromes is essential. Paragangliomas are now considered to be pioneer models of genetic-based personalised medical care.

Summary

This review aims to define the best current management plan for paragangliomas arising in, or involving, the temporal bone. It alerts surgeons to critical phases of surgical technique.

http://bit.ly/2FRV7Xj

Consumer Technology for Sleep-Disordered Breathing: a Review of the Landscape

Abstract

Purpose of Review

The consumer market for devices that quantify sleep is quickly evolving. We conducted a review of the consumer technology available for sleep disorders, including its potential and limitations to screen obstructive sleep apnea (OSA).

Recent Findings

There are many commercial devices claiming to objectively measure sleep, but only a few are tested rigorously in research. We critically review the technology available, including its overall ability to provide objective measures of sleep (total sleep time (TST), sleep efficiency (SE), sleep latency (SL), wake after sleep onset (WASO)), and to estimate apnea-hypopnea indexes in OSA patients.

Summary

Although consumer devices performed similarly to standard actigraphy, they still overestimated TST and SE, and underestimated WASO and SL. Biomotion sensors and mattress-based devices showed potential for use as an OSA screening tool. However, research in the sleep-disordered breathing (SDB) population is limited, needs further external validation, and should be implemented in the course of multiple days.

http://bit.ly/2G2Pdle

Drug-Induced Sleep Endoscopy as a Tool for Surgical Planning

Abstract

Purpose of Review

To review whether drug-induced sleep endoscopy (DISE) aids in obstructive sleep apnea surgical planning, if it changes the initial proposal, and if so, does it contribute to increased surgical success or unnecessary morbidity?

Recent Findings

A DISE and surgical outcomes multicenter cohort study (n = 275) reported no association for surgical outcomes with velopharyngeal and epiglottic collapse. Oropharyngeal and tongue base collapse on the other hand were associated with lower odds of surgical response.

Summary

DISE changes surgical planning mainly in regard to the approach of the tongue base and epiglottis, as these structures usually do not collapse in the awake state. The decision of velopharyngeal surgery usually does not change, as the vast majority demonstrate velopharyngeal collapse in DISE. Whether DISE increases or not, surgical success is controversial, with conflicting published data. However, poorer surgical outcomes have been associated with velopharyngeal concentric, oropharyngeal lateral wall, and tongue base collapse.

http://bit.ly/2FP5RFP

Clinical Outcomes in OSA—SLEEP GOAL—a More Holistic Approach

Abstract

Purpose of Review

Obstructive sleep apnea (OSA) is a systemic disease that is due to a narrow upper airway that collapses and obstructs during sleep, which results in frequent nocturnal hypoxemia, sympathetic overdrive, tachycardia, nocturnal hypertension, and oxidative metabolic stress. Symptoms include unrefreshed sleep, daytime tiredness, loss of memory, irritability, lack of concentration, poor work productivity, poor quality of life (QOL), mood swings, and even depression. This upper airway disorder can lead to systemic diseases such as hypertension, cardiovascular events, myocardial infarct, and fatal arrhythmias.

Recent Findings

The standard diagnostic test for OSA is commonly assumed to be the overnight polysomnography (PSG); however, it is widely known that there is discordance between the levels of AHI (apnea–hypopnea index) used to denote outcomes/success of therapy and real-world clinical outcomes such as QOL, patient perception of disease, cardiovascular measures, and/or survival.

Summary

Hence, the use of a single parameter AHI is inadequate and unrealistic; sleep specialists need more holistic and less biased parameters to assess treatment outcomes. Some of these parameters include snoring level, sleep satency, execution time, Epworth Sleepiness Scale, blood pressure, gross weight (BMI), oxygen duration below 90%, AHI, and QOL scores.

http://bit.ly/2G3jRv1

Frictional Keratosis, Contact Keratosis and Smokeless Tobacco Keratosis: Features of Reactive White Lesions of the Oral Mucosa

Abstract

White lesions of the oral cavity are quite common and can have a variety of etiologies, both benign and malignant. Although the vast majority of publications focus on leukoplakia and other potentially malignant lesions, most oral lesions that appear white are benign. This review will focus exclusively on reactive white oral lesions. Included in the discussion are frictional keratoses, irritant contact stomatitis, and smokeless tobacco keratoses. Leukoedema and hereditary genodermatoses that may enter in the clinical differential diagnoses of frictional keratoses including white sponge nevus and hereditary benign intraepithelial dyskeratosis will be reviewed. Many products can result in contact stomatitis. Dentrifice-related stomatitis, contact reactions to amalgam and cinnamon can cause keratotic lesions. Each of these lesions have microscopic findings that can assist in patient management.

http://bit.ly/2U9yVL4

A Rare Presentation of Inflammatory Myofibroblastic Tumor in the Nasolabial Fold

Inflammatory myofibroblastic tumor (IMT) is a benign lesion that occurs most frequently in the soft tissues and viscera. In the head and neck region, the tumor has been reported to occur in the orbit, tongue, nasopharynx, larynx, and paranasal sinuses and the central nervous system. Despite being a benign lesion, it exhibits infiltrative and destructive behaviours, making histopathological examination necessary to confirm the diagnosis. We report the case of a 38-year-old female presented with a right nasolabial fold mass, which was confirmed histologically to be an IMT. Surgical excision of the mass was achieved through a sublabial approach with an uneventful postoperative period. To the best of our knowledge, this is the first reported case of an IMT in the nasolabial fold.

http://bit.ly/2AX43X8

A Case of Respiratory Epithelial Adenomatoid Hamartoma (REAH) in a Patient with History of Radiation Exposure

Respiratory epithelial adenomatoid hamartomas (REAHs) are becoming a more commonly recognized otolaryngologic tumor and are often misdiagnosed as inverted papilloma. Here, we present such a case in a patient with history of previous radiation exposure. Otolaryngologists and pathologists should be aware of the mucinous histological appearance of REAH to help differentiate from other growths. Given our patient's history, an association between REAH and previous radiation exposure is worth consideration.

http://bit.ly/2Dppt0Y

Operative Therapie des frühen und fortgeschrittenen Ovarialkarzinoms

Zusammenfassung

Hintergrund

Die operative Therapie des Ovarialkarzinoms ist neben der systemischen Therapie ein grundlegender Pfeiler in der Behandlungsstrategie. Grundsätzlich hat die Operation eine duale Bedeutung: Sie dient zum einen als Grundlage des FIGO-Stagings und ist demnach die wichtigste diagnostische Methode. Andererseits hat sie unmittelbaren Einfluss auf die Prognose und ist Teil eines meist multimodalen und interdisziplinären Therapiekonzepts beim primären Ovarial‑, Tuben- und Peritonealkarzinom.

Ergebnisse

Während es sich in den frühen Stadien bis FIGO IIA mehrheitlich um Komplettierungs- sowie Staging-Operationen handelt, sollte das Ziel der Operation beim fortgeschrittenen Karzinom die maximale Tumorreduktion sein, häufig verbunden mit der Notwendigkeit multiviszeraler Eingriffe. Das operative Staging im Frühstadium bis FIGO IIA sollte adäquat sowie komplett durchgeführt werden und definierte Operationsschritte beinhalten. Da der verbleibende, makroskopisch sichtbare Tumorrest ein entscheidender Prognosefaktor für das Gesamtüberleben ist, sollte das Ziel der Operation im fortgeschrittenen Stadium immer eine makroskopische Komplettresektion sein. Bei Patientinnen mit fortgeschrittenem Ovarialkarzinom ab dem Stadium FIGO IIIC sollte bei klinisch unauffälligen Lymphknoten und einer makrokoskopischen Komplettresektion auf eine systematische pelvine und paraaortale Lymphonodektomie unbedingt verzichtet werden. Die primäre Operation gilt auch in der aktuellen interdisziplinär und interprofessionell abgestimmten S3-Leitlinie als Standardtherapie. Methoden wie PIPAC oder HIPEC sollten nicht außerhalb klinischer Studien zur Anwendung kommen.

Diskussion

Der postoperative Tumorrest ist der entscheidendste Prognosefaktor für das progressionsfreie und Gesamtüberleben. In den Frühstadien sollte ein adäquates Staging erfolgen, wohingegen in den häufigeren fortgeschrittenen Stadien multiviszerale Resektionen erforderlich sind, welche eine interdisziplinäre Zusammenarbeit erforderlich machen.

http://bit.ly/2FUgzuG

Therapieoptionen zum Ovarialkarzinom

http://bit.ly/2UdOsts

Anästhesiologische Aspekte beim Ovarialkarzinom

Zusammenfassung

Hintergrund

Die perioperative, anästhesiologische Betreuung von Ovarialkarzinompatientinnen im Rahmen von zytoreduktiven Operationen ist durch erkrankungsspezifische Komorbiditäten und therapieimmanente anästhesiologische Besonderheiten gekennzeichnet. Hierzu gehören z. B. eine mögliche präoperative Anämie, die perioperative Hypothermie oder eine mögliche Verdünnungskoagulopathie. Dabei stellen die intraoperative Flüssigkeits- und Volumensubstitution, Transfusion und Katecholamintherapie eine besondere anästhesiologische Herausforderung bei zytoreduktiven Operationen dar.

Ergebnisse

Bereits im Rahmen der präoperativen Evaluierung sollten erkrankungsspezifische Komorbiditäten wie Darmpassagehindernisse, maligner Aszites, Pleuraergüsse sowie präoperative Anämien diagnostiziert und ggf. therapiert werden. Ein präoperatives Vorwärmen der Patienten mindert das Risiko einer Redistributionshypothermie bei Narkoseeinleitung und damit das Risiko einer perioperativen Hypothermie und Nachbeatmung. Bei mangelnder Evidenz für oder gegen die ausschließliche Nutzung balancierter Vollelektrolytlösung empfiehlt sich eine bedarfsadaptierte Flüssigkeitssubstitution in Verbindung mit dem Einsatz von kolloidalen Infusionslösungen und ggf. Substitution von gefrorenem Frischplasma (GFP) und Applikation von Antifibrinolytika. Insbesondere bei präoperativ bestehendem malignem Aszites und im Rahmen einer intraoperativen Deperitonealisierung mit zu erwartenden großen Volumenverlusten kann der Einsatz eines erweiterten hämodynamischen Monitorings zur zielgerichteten Volumentherapie indiziert sein.

Schlussfolgerungen

Die perioperative anästhesiologische Versorgung sollte dem individuellen und für das Ovarialkarzinom typischen Risikoprofil angepasst werden. Um dem u. a. durch ausgeprägte operative Deperitonealisierung und Aszites ausgelösten Proteinverlust Rechnung zu tragen, empfiehlt sich eine präoperative Optimierung des Allgemeinzustands der Patientinnen. Eine bedarfsgerechte Volumentherapie und der perioperative Wärmeerhalt spielen hierbei eine zentrale Rolle.

http://bit.ly/2DCtq2j

Behandlung ausgedehnter Lokalrezidive der Mundhöhle und des Oropharynx

Zusammenfassung

Hintergrund

Die Behandlung ausgedehnter Lokalrezidive der Mundhöhle und des Oropharynx gehört zu den größten Herausforderungen in der onkologischen Therapie der Kopf-Hals-Region. In der Regel erhielten diese Patienten im Rahmen der Therapie ihres Primärtumors neben einer chirurgischen Resektion bereits eine adjuvante Radiotherapie. Aus diesem Grund ist eine erneute Bestrahlung der rezidivierenden Karzinome häufig nur noch in palliativer Intention möglich. Da trotz erstaunlicher Fortschritte in der Entwicklung moderner Wirkstoffe aktuell auch die medikamentöse Systemtherapie lediglich der Symptomkontrolle dienen kann, hat die Rettungschirurgie in diesen Fällen den bedeutendsten Stellenwert.

Schlussfolgerungen

Die wichtigste Voraussetzung für die Durchführung einer solchen radikalen rettungschirurgischen Operation ist allerdings, dass es in der Tumorumfelddiagnostik keine Hinweise auf das Vorliegen von Fernmetastasen gibt. Darüber hinaus ist prätherapeutisch unbedingt zu klären, ob eine R0-Resektion mit ausreichendem Sicherheitsabstand möglich sein wird, ohne vital notwendige Strukturen wie das Hirngewebe versorgende Endarterien oder essenziell zu erhaltende Anteile des Neurokraniums zu gefährden. Auch ist darauf zu achten, dass bei der ablativen Therapie der Erhalt oder die Wiederherstellung von wichtigen Funktionen wie Sprechen und Schlucken berücksichtigt wird. Daher ist eine solche radikal-chirurgische Maßnahme nur durch die sofortige Rekonstruktion des entfernten Gewebes durch z. T. ausgedehnte osteomyokutane Transplantate gerechtfertigt. Hier ist das gesamte Spektrum der rekonstruktiven Kopf-Hals-Chirurgie inklusive diversifizierter mikrovaskulärer Techniken vorzuhalten, um dem individuellen Patient sowohl eine langfristige Prognose zu schaffen als auch eine angemessene Lebensqualität zu erhalten.

http://bit.ly/2Uhj0KX

Hypoparathyreoidismus – eine Belastung für die Patienten

Zusammenfassung

Hypoparathyreoidismus (HPT) ist eine der häufigsten Komplikationen einer Schilddrüsenkrebsoperation. Die Lebensqualität von Patienten mit HPT ist im Vergleich zu Normpopulationen oder gematchten Kontrollindividuen stark eingeschränkt. Eine reduzierte Lebensqualität zeigt sich gleichermaßen in physischen und psychischen Bereichen. Wenige Studien haben bisher die Lebensqualität von Schilddrüsenkrebsüberlebenden mit postoperativem HPT erhoben. Einschränkungen der Lebensqualität von Patienten mit postoperativem HPT nach Schilddrüsenkrebs lassen sich nicht nur durch die Erkrankung Krebs und ihre Behandlung erklären, sondern auch durch HPT selbst. Weitere Forschung in Bezug auf die Therapie von HPT in Deutschland und die Lebensqualität von HPT-Patienten nach Schilddrüsenkrebs ist erforderlich. HPT ist die einzige endokrine Funktionsstörung, bei der das fehlende Hormon im Rahmen der Standardtherapie nicht ersetzt werden kann. Die aktuelle Therapie besteht aus Kalzium- und Vitamin-D-Analogen unter regelmäßiger Überprüfung von Laborwerten. Die empfohlene Überprüfung der Blutwerte muss häufiger durchgeführt werden als es im Rahmen von regulären Krebsnachsorgeuntersuchungen möglich wäre. Es gibt aktuell keine systematischen Erhebungen, wie HPT-Patienten in Deutschland behandelt werden.

http://bit.ly/2DAG5Tg

The Impact of Immunodeficiency on NK Cell Maturation and Function

Abstract

Purpose of Review

Natural killer cells are innate lymphoid cells (ILCs) that play critical roles in human host defense and are especially useful in combating viral pathogens and malignancy.

Recent Findings

The NK cell deficiency (NKD) is particularly underscored in patients with a congenital immunodeficiency in which NK cell development or function is affected. The classical NK cell deficiency (cNKD) is a result of absent or a profound decrease in the number of circulating NK cells. In contrast, functional NKD (fNKD) is characterized by abnormal NK cell function but with normal number of NK cells. The combined immune deficiencies with significant impact on NK cells are not considered classical or functional NK cell deficiencies. In these disorders, the impairment of NK cells represents an important aspect of the overall immunodeficiency. In turn, this leads to improved insights on the NK cell development and function.

Summary

Here, we detail the NK cell biology based upon recent natural killer cell defects described in combined immune deficiencies.

http://bit.ly/2T6b0ME

Direct to Consumer Telemedicine

Abstract

Purpose of Review

Telemedicine uses technology to connect patients and data with providers at a distance. Direct to consumer telemedicine is a rapidly growing segment of the industry.

Recent Findings

The telehealth market has skyrocketed in recent years, making it a multi-billion dollar industry. Direct to consumer telehealth, dominated by the for-profit private sector, is the most popular form.

Summary

Direct to consumer telemedicine is a subset of telehealth that shows promise in increasing access to and engagement in medical care. Quality assurance, reimbursement, and regulatory oversight are important factors in assuring appropriate widespread adoption.

http://bit.ly/2AS1sOg

Hepatic arterial infusion of irinotecan and EmboCept ® S results in high tumor concentration of SN-38 in a rat model of colorectal liver metastases

Abstract

Intraarterial chemotherapy for colorectal liver metastases (CRLM) can be applied alone or together with embolization particles. It remains unclear whether different types of embolization particles lead to higher intratumoral drug concentration. Herein, we quantified the concentrations of CPT-11 and its active metabolite SN-38 in plasma, liver and tumor tissue after hepatic arterial infusion (HAI) of irinotecan, with or without further application of embolization particles, in a rat model of CRLM. Animals underwent either systemic application of irinotecan, or HAI with or without the embolization particles Embocept^® S and Tandem™. Four hours after treatment concentrations of CPT-11 and SN-38 were analyzed in plasma, tumor and liver samples by high-performance liquid chromatography. Additionally, DNA-damage and apoptosis were analyzed immunohistochemically. Tumor tissue concentrations of SN-38 were significantly increased after HAI with irinotecan and EmboCept^® S compared to the other groups. The number of apoptotic cells was significantly higher after both HAI with irinotecan and EmboCept^® S or Tandem™ loaded with irinotecan compared to the control group. HAI with irinotecan and EmboCept^® S resulted in an increased SN-38 tumor concentration. Both HAI with irinotecan and EmboCept^® S or Tandem™ loaded with irinotecan were highly effective with regard to apoptosis.

http://bit.ly/2Mxl4vN

Meeting report: Metastasis Research Society (MRS) 17th Biennial conference and associated Young Investigator Satellite Meeting (YISM) on cancer metastasis

Abstract

The Metastasis Research Society (MRS) 17th Biennial conference on metastasis was held on the 1st to the 5th of August 2018 at Princeton University, NJ, USA. The meeting was held around themes addressing notable aspects of the understanding and treatment of metastasis and metastatic disease covering basic, translational, and clinical research. Importantly, the meeting was largely supported by our patient advocate partners including Susan G. Komen for the Cure, Theresa's Research Foundation and METAvivor. There were a total of 85 presentations from invited and selected speakers spread across the main congress and presentations from the preceding Young Investigator Satellite Meeting. Presentations are summarized in this report by session topic.

http://bit.ly/2sQnxbG

VideoEndocrinology™ New Open Access Video

Parapharyngeal Dissection for Papillary Thyroid Cancer
Justin Tran, Mark Zafereo 

The post VideoEndocrinology™ New Open Access Video appeared first on American Thyroid Association.

http://bit.ly/2T4XFEg

VideoEndocrinology™ New Open Access Video

Parapharyngeal Dissection for Papillary Thyroid Cancer
Justin Tran, Mark Zafereo 

The post VideoEndocrinology™ New Open Access Video appeared first on American Thyroid Association.

http://bit.ly/2T4XFEg

Long-term outcome of hyperthyroidism diagnosed in childhood and adolescence: a single-centre experience

Journal Name: Journal of Pediatric Endocrinology and Metabolism
Issue: Ahead of print


http://bit.ly/2S6JgKK

Hepatopathies in children and adolescents with type 1 diabetes

Journal Name: Journal of Pediatric Endocrinology and Metabolism
Issue: Ahead of print


http://bit.ly/2HA4mgf

Functional and endocrine-metabolic oligomenorrhea: proposal of a new diagnostic assessment tool for differential diagnosis in adolescence

Journal Name: Journal of Pediatric Endocrinology and Metabolism
Issue: Ahead of print


http://bit.ly/2S86xMc

Long-term spatiotemporal variations of atmospheric sulfur, nitrogen and particle pollutants in Chongqing, southwest China: implication of industrial transfer

Abstract

Industrial transfer has swept through in China. However, there is still a knowledge gap about its environmental effects. In this study, industrial transfer status was assessed and evaluated by industrial ratios (%; the gross product contributions of the secondary industry to the whole industry) and the impact of such transfer on atmospheric environment (SO₂, NO₂, PM₁₀ (particles with aerodynamic diameter less than 10 μm), precipitations of SO₄²⁻, NO₃⁻, and NH₄⁺) in the 38 districts and counties in Chongqing was analyzed and discussed for the period of 2006–2015. Results showed that industries were transferred obviously from the main urban region (MUR) into the 1-h economic region (OHER). Atmospheric sulfur and PM₁₀ were efficiently put in control, but atmospheric nitrogen (NO₂; precipitations of NO₃⁻ and NH₄⁺) was increasing and posted a potential threat to air quality especially during 2011–2015. Correlations showed that industrial ratios had significantly positive relationships with concentrations of ambient SO₂ and PM₁₀ in the MUR and ambient NO₂ in the OHER (p < 0.05) while a remarkably negative one with concentrations of ambient SO₂ in the OHER (p < 0.05) during 2006–2015, implying that industrial transfer could be effective in transferring sulfur pollution but not as efficient in transferring atmospheric nitrogen and PM₁₀ pollutions as SO₂ between in the MUR and OHER. More measures should be taken to reduce nitrogen and PM₁₀ emission and a regional monitoring network of ambient NH₃ is in urgent need.

http://bit.ly/2G2LR1z

Real-world drug survival of ixekizumab for psoriasis

Publication date: Available online 26 January 2019

Source: Journal of the American Academy of Dermatology

Author(s): Erica B. Lee, Deeti J. Pithadia, Kelly A. Reynolds, Shivani P. Reddy, Alexander Egeberg, Jashin J. Wu

http://bit.ly/2B2K8pS

Pharmacy Costs of Medications for the Treatment of Onychomycosis in the United States

Publication date: Available online 26 January 2019

Source: Journal of the American Academy of Dermatology

Author(s): Eric J. Yang, Shari R. Lipner

http://bit.ly/2Tkga84

A Comparison of the Efficacy of Ablative Fractional Laser Assisted Photodynamic Therapy according to Ablative Depth for Actinic Keratosis: A Single-blinded, Randomized, Comparative, Prospective Study

Publication date: Available online 26 January 2019

Source: Journal of the American Academy of Dermatology

Author(s): Jeong-Wan Seo, Ho-Jin Kim, Ki-Hoon Song

http://bit.ly/2B60huR

New Insights into the Utility of Omalizumab

Publication date: Available online 26 January 2019

Source: Journal of Allergy and Clinical Immunology

Author(s): Juan Carlos Cardet, Thomas B. Casale

http://bit.ly/2RgsN27

Effects of continuous and intermittent parathyroid hormone administration on midpalatal suture expansion in rats

Publication date: Available online 25 January 2019

Source: Archives of Oral Biology

Author(s): Jianru Yi, Li Mei, Xue Li, Wei Zheng, Yu Li, Zhihe Zhao

Abstracts

Objectives

The aim of this study was to investigate the effects of continuous parathyroid hormone (cPTH) and intermittent parathyroid hormone (iPTH) on bone formation and bone resorption in midpalatal suture during maxillary expansion.

Methods

Forty-eight male SD rats were randomly divided into four groups (n = 12 each), including the control, the expansion (E), the E + cPTH, and the E + iPTH. A thermosensitive controlled-release hydrogel was synthesized for cPTH administration. All animals were sacrificed after seven days. Microcomputed tomography, histochemical staining and real-time PCR were used to investigate the bone remodeling of midpalatal suture. Serum chemistry was adopted to evaluate the systemic condition of experimental animals.

Results

The suture width was increased by the expansion, and further elevated by cPTH and iPTH administration. Both regimes improved bone volume fraction and trabecular thickness of suture bone region. Moreover, both cPTH and iPTH decreased SOST expression and enhanced the expression of β-catenin and Col-I. cPTH increased RANKL expression, inhibited OPG expression, and resulted in an increment of osteoclasts, while iPTH had no influence on osteoclastogenesis. The serum calcium concentration was enhanced by PTH administration.

Conclusion

Both cPTH and iPTH promote midpalatal suture expansion by enhancing bone formation, probably via SOST downregulation and the resulting β-catenin activation. Our results demonstrated that PTH administration may have potential to be an adjunctive approach for maxillary expansion treatment.

http://bit.ly/2ROJAOX

Editorial Board

Publication date: February 2019

Source: Journal of Autoimmunity, Volume 97

Author(s):

http://bit.ly/2HwfavO

Androgens modulate keratinocyte differentiation indirectly through enhancing growth factor production from dermal fibroblasts

Publication date: Available online 26 January 2019

Source: Journal of Dermatological Science

Author(s): Chanat Kumtornrut, Takeshi Yamauchi, Saaya Koike, Setsuya Aiba, Kenshi Yamasaki

Abstract

Background

The main pathogenesis of acne vulgaris is increase in sebum production and abnormal keratinization of the hair infundibulum. The androgens are involved in acne pathogenesis by modulating sebaceous glands to enhance sebum production. However, the molecular mechanisms of abnormal keratinization of the hair infundibulum are not fully elucidated.

Objective

We hypothesized that the androgens affect the dermal fibroblasts, another androgen receptor-positive cells in the skin, resulting in abnormal keratinization through keratinocyte-fibroblast interaction.

Methods

We investigated effects of androgens and estrogens on growth factors expressions by RT-PCR and western blot analysis in human fibroblast (hFB), human keratinocyte (hKC), and fibroblast-keratinocyte co-culture. In vivo, we examined the growth factor expression in acne lesions compared to normal hair follicles by laser-assisted confocal microscope.

Results

In vitro, androgens but not estrogens significantly increased amphiregulin (AREG), epiregulin (EREG), fibroblast growth factor (FGF) 10, and insulin-like growth factor binding protein (IGFBP) 5 mRNA and protein expressions in human fibroblasts but not in keratinocytes. In vivo, AREG, EREG, FGF10, and IGFBP5 were more abundant in acne lesion compared to normal facial skin. FGF10 suppressed cytokeratin 1 and cytokeratin 10 expression in hKC, which was along with the decreased ratio of cytokeratin 10 against cytokeratin 14 in acne lesions compared to normal facial skin. Also, DHT suppressed cytokeratin 1 and cytokeratin 10, in fibroblast-keratinocyte co-culture similarly to the effect of FGF10 to hKC.

Conclusion

These observations suggested that androgens enhance growth factors production from dermal fibroblasts, and growth factors from fibroblasts alter keratinocyte differentiation in acne lesion.

http://bit.ly/2Hvf33P

Rare Risky Recurrent: An Enigmatous Cutaneous Polyp

Myxofibrosarcomas (MFS) are sarcomas most commonly seen in older patients. These are tumors of deep soft tissue seen in subcutaneous tissue, deep fascia with frequent muscle involvement. These sarcomas are notorious for recurrences, progression to a higher grade with notable metastatic potential. It is very often under‐diagnosed owing to its inherent morphological variability. A case of MFS is presented as a cutaneous, exophytic, polypoidal mass because of its rarity and importance of timely diagnosis, as under diagnosis may lead to inadequate clearance of tumor, recurrences, metastases and increased mortality.

This article is protected by copyright. All rights reserved.

http://bit.ly/2HvpMuT

“IgG/IgA Pemphigus in a Patient with a History of Pemphigus Vulgaris: An Example of Epitope Spreading?

The dual presentation of IgG and IgA positivity on direct immunofluorescence (DIF) constitutes a rare form of pemphigus. IgG/IgA pemphigus varies widely in clinical and pathologic presentation. Reported sites of involvement range from the trunk as the sole site of involvement to the whole body and oral mucosa as well as the conjunctiva and esophagus¹.

This article is protected by copyright. All rights reserved.

http://bit.ly/2S9Z5Af

Tissue sodium concentration and sodium T1 mapping of the human brain at 3 T using a Variable Flip Angle method

Publication date: Available online 26 January 2019

Source: Magnetic Resonance Imaging

Author(s): Arthur Coste, Fawzi Boumezbeur, Alexandre Vignaud, Guillaume Madelin, Kathrin Reetz, Denis Le Bihan, Cécile Rabrait-Lerman, Sandro Romanzetti

Abstract

Purpose

The state-of-the-art method to quantify sodium concentrations in vivo consists in a fully relaxed 3D spin-density (SD) weighted acquisition. Nevertheless, most sodium MRI clinical studies use short-TR SD acquisitions to reduce acquisition durations. We present a clinically viable implementation of the Variable Flip Angle (VFA) method for robust and clinically viable quantification of total sodium concentration (TSC) and longitudinal relaxation rates in vivo in human brain at 3 T.

Methods

Two non-Cartesian steady-state spoiled ultrashort echo time (UTE) scans, performed at optimized flip angles, repetition time and pulse length determined under specific absorption rate constraints, are used to simultaneously compute T₁ and total sodium concentration (TSC) maps using the VFA method. Images are reconstructed using the non-uniform Fast Fourier Transform algorithm and TSC maps are corrected for possible inhomogeneity of coil transmission and reception profiles. Fractioned acquisitions are used to correct for potential patient motion. TSC quantifications obtained using the VFA method are validated at first in comparison with a fully-relaxed SD acquisition in a calibration phantom. The robustness of similar VFA acquisitions are compared to the short-TR SD approach in vivo on seven healthy volunteers.

Results

The VFA method resulted in consistent TSC and T₁ estimates across our cohort of healthy subjects, with mean TSC of 38.1 ± 5.0 mmol/L and T₁ of 39.2 ± 4.4 ms. These results are in agreement with previously reported values in literature TSC estimations and with the predictions of a 2-compartment model. However, the short-TR SD acquisition systematically underestimated the sodium concentration with a mean TSC of 31 ± 4.5 mmol/L.

Conclusion

The VFA method can be applied successfully to image sodium at 3 T in about 20 min and provides robust and intrinsically T₁-corrected TSC maps.

http://bit.ly/2FOFKig

Eigenvector-based SPIRiT Parallel MR Imaging Reconstruction based on ℓp pseudo-norm Joint Total Variation

Publication date: Available online 25 January 2019

Source: Magnetic Resonance Imaging

Author(s): Jizhong Duan, Zhongwen Bao, Yu Liu

Abstract

Parallel Magnetic Resonance (MR) imaging is a well-established acceleration technique based on the spatial sensitivities of array receivers. Eigenvector-based SPIRiT (ESPIRiT) is a new parallel MR imaging reconstruction method that combines the advantages of the SENSE and GRAPPA methods. It estimates multiple sets of the sensitivity maps from the calibration matrix that is constructed from the auto-calibration data. To improve the quality of the reconstructed image, we introduced the Total Variation (TV) and ℓ_p pseudo-norm Joint TV (ℓ_pJTV) regularization terms to the ESPIRiT model for parallel MR imaging reconstruction, which were solved by using the Operator Splitting (OS) method. The resulting denoising problems with the TV and ℓ_pJTV regularization terms were solved by exploiting the majorization minimization method. Simulation experiments on two in vivo data sets demonstrated that the proposed OS algorithm with the TV regularization term (OSTV) and OS algorithm with the ℓ_pJTV regularization term (OSℓ_pJTV) outperformed the conventional method with the ℓ₁ regularization term in terms of SNR and NRMSE. And the OSℓ_pJTV algorithm was slightly superior to the OSTV algorithm with the TV regularization term.

http://bit.ly/2G3Eln5

Traitement des kystes épidermoïdes du scrotum par laser CO2 : deux cas et revue de la littérature

Publication date: Available online 26 January 2019

Source: Annales de Dermatologie et de Vénéréologie

Author(s): E. Bahloul, M. Mseddi, F. Hammemi, K. Souid, M. Amouri, H. Turki

Résumé

Introduction

Les kystes épidermiques scrotaux sont des tumeurs bénignes du scrotum. Le caractère chronique de ces lésions, leur aspect inesthétique et leur survenue chez des sujets jeunes s'accompagnent souvent d'un retentissement psychologique. Nous rapportons deux cas de kystes épidermoïdes scrotaux traités par le laser CO₂ en mode superpulsé.

Observations

Les paramètres utilisés étaient une puissance de respectivement 10 et 10,8 W pour une durée de pulse de 20 ms avec une durée de pause similaire. Les séances étaient réalisées après anesthésie locale par lidocaïne. Une à deux séances de 10 minutes étaient nécessaires pour traiter tous les kystes. Des soins locaux à base de corps gras et d'antibiotique local étaient prescrits après la séance laser. Les résultats esthétiques étaient excellents, satisfaisant nos patients. Aucune complication ou récidive n'a été notée. Nous avons également traité de la même manière un patient ayant un kyste scrotal unique, avec des résultats excellents et sans complication ni récidive.

Discussion

Une revue exhaustive de la littérature a été réalisée à partir du moteur de recherche PubMed^® avec les mots clés « EpidermalCyst », « lasers » et « scrotum ». Seuls deux cas cliniques de kystes scrotaux traités par laser étaient rapportés, un avec un laser Nd-YAG et l'autre avec un laser Diode. L'utilisation du laser CO₂ n'a pas été rapportée dans le traitement des kystes épidermoïdes scrotaux, alors qu'elle semble permettre un traitement efficace et sans récidive.

Summary

Background

Epidermal cyst is a common cutaneous lesion that may be located in the scrotum and is seen especially in young and middle-aged men. This entity is not only chronic but can also affect the patient's appearance, thus having an impact on their quality of life. Surgical excision is the classical procedure to remove such cysts, but it can be time-consuming and leave unpleasant scars. In this report, we included patients with scrotal cysts treated with the CO₂ laser.

Patients and methods

This study reports on two patients referred with epidermal scrotal cysts in whom CO₂ laser was used in superpulse mode at 10 to 10.8 W and with a pulse duration of 20 ms. The session was performed after local anesthesia with lidocaine. One to two 10-minute sessions were required to treat all cysts. All the patients were satisfied with the cosmetic results and no complications or recurrences were observed at follow-up. We also treated a patient with a single scrotal cyst in the same way, with excellent results.

Discussion

A literature review was performed using the Medline database. It revealed only two case reports involving scrotal cysts treated with laser using Nd-YAG laser and Diode Laser. There is no reported use of CO₂ laser in the treatment of scrotal cysts. Its use in superpulsed mode in the cases we describe is innovative. This procedure appears to be a safe, tolerable, and efficacious approach for the removal of epidermal scrotal cysts resulting in excellent cosmetic results and without recurrence.

http://bit.ly/2Re206s

Érythème généralisé fébrile et choc : choc toxinique staphylococcique

Publication date: Available online 26 January 2019

Source: Annales de Dermatologie et de Vénéréologie

Author(s): P.-M. Dugourd, A. Dupont, T. Hubiche, C. Chiaverini, A. Alkhalifa, L. Roudiere, A. Tristan, C.-A. Gustave, P. Del Giudice

Résumé

Introduction

Le toxic shock syndrome (TSS) a été décrit pour la première fois par Todd en 1978. Cette publication du Lancet rapportait 7 cas d'enfants présentant une fièvre, un exanthème, une hypotension et une diarrhée associés à une défaillance multiviscérale. C'est dans les années 1980 qu'une association entre TSS et femmes en période de menstruation utilisant des tampons hyperabsorbants a été découverte. Après le retrait du marché de ce type de tampon, le TSS a quasiment disparu. Nous rapportons un nouveau cas de TSS survenu chez une adolescente.

Observation

Une jeune fille de 15 ans était hospitalisée en réanimation pour un tableau brutal de choc septique avec troubles de la vigilance et douleurs abdominales diffuses. L'examen dermatologique trouvait un exanthème maculeux diffus. Le bilan biologique montrait une cytolyse hépatique (ASAT 101 U/L, ALAT 167 U/L, bilirubine totale 68 μmol/L) et un syndrome inflammatoire. La ponction lombaire et les hémocultures étaient stériles. La tomodensitométrie cérébrale et thoraco-abdomino-pelvienne était normale. Dans un contexte de menstruation, la patiente avait utilisé un tampon hygiénique plus de 24 h. Le prélèvement vaginal et la culture du tampon mettaient en évidence un S. aureus producteur de la toxine TSST-1. La prise en charge consistait en mesures de réanimation et traitement par une association amoxicilline-acide clavulanique et clindamycine pendant 10 jours.

Conclusion

Un tableau de choc septique associé à un exanthème maculeux diffus doit faire évoquer le diagnostic de TSS, surtout dans un contexte menstruel.

Summary

Background

Toxic shock syndrome (TSS) was first described by Todd in 1978. The relevant Lancet publication reported 7 cases of children with fever, exanthema, hypotension and diarrhoea associated with multiple organ failure. An association between TSS and use of hyper-absorbent tampons in menstruating women was discovered in the 1980s. Following the market withdrawal of such tampons, TSS virtually disappeared. Herein we report a new case of TSS in a 15-year-old girl.

Patients and methods

A 15-year-old patient was admitted to intensive care for severe sepsis and impaired consciousness associated with diffuse abdominal pain. Dermatological examination revealed diffuse macular exanthema. Laboratory tests showed hepatic cytolysis (ASAT 101 U/L, ALAT 167 U/L, total bilirubin 68 μmol/L) and an inflammatory syndrome. Lumbar puncture and blood cultures were sterile while thoraco-abdomino-pelvic and brain scans were normal. The patient was menstruating and had been using a tampon over the previous 24 hours. Vaginal sampling and tampon culture revealed TSST-1 toxin-producing S. aureus. Management consisted of intensive care measures and treatment with amoxicillin-clavulanic acid and clindamycin for 10 days.

Conclusion

In case of septic shock associated with diffuse macular exanthema a diagnosis of TSS must be envisaged, particularly in menstruating women.

http://bit.ly/2WllVE8

Hamartome folliculaire basaloïde : étude anatomoclinique

Publication date: Available online 26 January 2019

Source: Annales de Dermatologie et de Vénéréologie

Author(s): G. Hazemann, C. Michel, A. Mahé, D. Lipsker, B. Cribier

Résumé

Introduction

L'hamartome folliculaire basaloïde (HFB) est une tumeur rare décrite en 1985. Elle possède des similarités cliniques et histologiques avec le carcinome basocellulaire (CBC), notamment infundibulo-kystique. Nous avons effectué une étude anatomoclinique monocentrique de cette entité de diagnostic parfois difficile.

Patients et méthodes

Les cas classés HFB au laboratoire de dermatopathologie de Strasbourg ont été inclus et analysés en coloration hématoxyline-éosine et avec les immunomarquages Ber-EP4 et PHLDA1. Le diagnostic était retenu lorsqu'il existait des formations épithéliales arborescentes développées à partir d'un follicule pileux. Les renseignements cliniques ont été collectés à partir des demandes d'analyse et des dossiers cliniques.

Résultats

Nous avons retenu 15 cas survenus chez 13 patients. L'âge moyen était de 44,8 ans et le sex-ratio de 5/8. Il s'agissait de papules de couleur chair, rose ou brune, mesurant 0,3 à 1,2 cm, sans localisation préférentielle. Trois patientes avaient des lésions multiples, groupées sur un sein dans un cas, diffuses sur le dos dans un cas et hémicorporelles et linéaires, associés à des anomalies squelettiques, réalisant le tableau du syndrome de Happle-Tinschert dans un cas. Tous les HFB étaient limités au derme superficiel et moyen, formés d'éléments épithéliaux basophiles arborescents, verticaux dans deux tiers des cas et connectés à l'épiderme dans 14 cas. Des zones périphériques plus basophiles et centrales plus éosinophiles, une organisation palissadique et des fentes de rétraction à distance, entre le stroma et le derme, étaient fréquemment observées. Il y avait toujours des kystes épidermoïdes ou des structures sébacées orientant vers une origine folliculaire. L'immunomarquage Ber-EP4 était positif uniquement en périphérie des lobules tumoraux et PHLDA1 n'était que très peu exprimé.

Discussion

L'HFB est une entité unique et distincte du CBC. Il peut être solitaire, isolé. Il peut aussi être multiple, à disposition linéaire unilatérale, éventuellement associé à des manifestations extracutanées homolatérales dans le cadre du syndrome d'Happle-Tinschert. Il peut enfin être multiple et généralisé, parfois accompagné de maladies auto-immunes. Il est important de le différencier du CBC, car il est bénin.

Summary

Introduction

Basaloid follicular hamartoma (BFH) is a rare tumor first described in 1985. It bears clinical and histologic similarities with basal cell carcinoma (BCC), in particular the so-called infundibulocystic form. We performed a single-center clinicopathological study of a series of typical cases of this entity that is occasionally difficult to diagnose.

Materials and methods

All cases of BFH seen at the Dermatopathology Laboratory of Strasbourg University Hospital were included and analyzed by means of HE staining and Ber-EP4 and PHLDA1 immunolabelling. Diagnosis was made in the event of basaloid proliferation with anastomosing cords developed from a hair follicle. Clinical data were collected from clinical files.

Results

We identified 15 cases in 13 patients of mean age 44.8 years (range: 4 to 90) and the sex-ratio was 5/8. Lesions consisted of flesh-colored papules measuring 0.3 to 1.2 cm in diameter, without any preferential site. Three patients had multiple lesions consisting of several coalescent papules on a breast for one, sparse papules on the back for another, and hundreds of linear unilateral BFHs, associated with osseous abnormalities, characteristic of Happle-Tinschert syndrome, for the third. All tumors were limited to the superficial and mid dermis, with a vertical orientation and connection to the epidermis in 14 of the 15 patients. In some cases, the outermost cells were basophilic while the central cells were eosinophilic. Peripheral palisading and clefting were frequently observed. Keratin cysts or sebaceous ducts were consistently present, indicating follicular differentiation. Ber-EP4+ cells were restricted to the periphery of the cords and PHLDA1 was weakly expressed.

Discussion

BFH is a rare entity that must be differentiated from BCC. It presents as solitary or multiple lesions, either grouped in plaques or with a generalized or linear unilateral distribution. Generalized BFH may be associated with autoimmune diseases and linear unilateral BFH with osseous, dental and cerebral abnormalities in Happle-Tinschert syndrome. It is important to distinguish BFH from BCC to avoid inappropriate aggressive treatment.

http://bit.ly/2Rf7RIE

Un intérêt inédit pour le prurigo nodulaire

Publication date: Available online 26 January 2019

Source: Annales de Dermatologie et de Vénéréologie

Author(s): L. Misery

http://bit.ly/2WnT3uS

Precursor B-cell development in bone marrow of Good syndrome patients

Publication date: Available online 25 January 2019

Source: Clinical Immunology

Author(s): Lucía del Pino Molina, Marjolein Wentink, Marcel van Deuren, Martin van Hagen, C.I. Edvard Smith, Mirjam van der Burg

Abstract

Good syndrome is an immunodeficiency presenting with thymoma, hypogammaglobulinemia and almost absent B cells. To investigate the origin of the B-cell lymphopenia in these patients, we studied B cell differentiation in the bone marrow of Good syndrome patients. We found very low numbers of precursor B cells in bone marrow of Good syndrome patients and a differentiation arrest after the pro-B-cell stage; this is different from other agammaglobulinemia patients with a defect in pre B-cell receptor signaling.

http://bit.ly/2TfUolD

Endoplasmic Reticulum Stress, the Hypothalamus, and Energy Balance

Publication date: Available online 25 January 2019

Source: Trends in Endocrinology & Metabolism

Author(s): Isin Cakir, Eduardo A. Nillni

Overweight and obesity pose significant health problems globally, and are causatively linked to metabolic dysregulation. The hypothalamus integrates neural, nutritional, and hormonal cues to regulate homeostasis, including circadian rhythm, body temperature, thirst, food intake, energy expenditure, and glucose metabolism. Hypothalamic neuropeptides play a fundamental role in these processes. Studies during the past two decades suggest a role of central endoplasmic reticulum (ER) stress in the pathophysiology of obesity. This review covers recent findings on the role of ER stress and neuropeptide processing in the central regulation of energy homeostasis, with special emphasis on proopiomelanocortin (POMC)-encoding neurons. In addition, the role of neuroinflammation in the context of obesity is briefly discussed.

http://bit.ly/2FQhNaj

Corrigendum to “Long-term survival and late toxicities of elderly nasopharyngeal carcinoma (NPC) patients treated by high-total- and fractionated-dose simultaneous modulated accelerated radiotherapy with or without chemotherapy” [Oral Oncol. 89 (2019) 40–47]

Publication date: Available online 26 January 2019

Source: Oral Oncology

Author(s): Jingjing Miao, Lin Wang, Manyi Zhu, Weiwei Xiao, Haijun Wu, Muping Di, Yuqing Huang, Shaomin Huang, Fei Han, Xiaowu Deng, Xiang Guo, Chong Zhao

http://bit.ly/2RecqTv

Reprint of Long-term survival and late toxicities of elderly nasopharyngeal carcinoma (NPC) patients treated by high-total- and fractionated-dose simultaneous modulated accelerated radiotherapy with or without chemotherapy

Publication date: Available online 25 January 2019

Source: Oral Oncology

Author(s): Jingjing Miao, Lin Wang, Manyi Zhu, Weiwei Xiao, Haijun Wu, Muping Di, Yuqing Huang, Shaomin Huang, Fei Han, Xiaowu Deng, Xiang Guo, Chong Zhao

Abstract

Background

To analyse the survival and late toxicities of elderly nasopharyngeal carcinoma (NPC) patients treated by intensity-modulated radiotherapy (IMRT) with the high-total- and fractionated-dose simultaneous modulated accelerated radiation therapy (SMART) boost technique and to identify the effect of concurrent chemotherapy for these patients.

Methods

Two hundred and fifty-four elderly patients (age ≥ 60.0) with newly diagnosed non-metastatic NPC were retrospectively analysed. Statistical analyses were performed using the SPSS software program.

Results

The actual mean total and fractionated doses delivered to the gross tumour volume of the nasopharynx (GTVnx) were 74.55 Gy and 2.49 Gy, respectively. The 5-year locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), disease-specific survival (DSS) and overall survival (OS) of the whole cohort were 93.0%, 85.7%, 83.2% and 74.1%, respectively. No grade 4 acute or late radiotherapy-induced toxicities were observed. Of 247 patients with stage II–IVb disease, 89 patients received radiotherapy (RT) alone, and 158 patients received concurrent chemoradiotherapy (CCRT), and the 5-year LRRFS, DMFS, DSS and OS of the RT-alone group vs. the CCRT group were 94.0% vs. 92.2%, 83.5% vs. 86.2%, 81.8% vs. 83.1% and 74.0% vs. 72.8% (all P > 0.05), respectively. Multivariate analyses showed that CCRT was not an independent predictor for LRRFS, DMFS, DSS and OS (all P > 0.05).

Conclusion

High-total- and fractionated-dose SMART boost IMRT could obtain a satisfactory long-term outcome with mild late toxicity in elderly NPC patients. The role of CCRT needs to be further studied to optimize the treatment strategy and improve the overall survival.

http://bit.ly/2Wt5lT4

Health-related quality of life in patients with cleft palate: reproducibility, responsiveness and construct validity of the Dutch version of the VELO questionnaire

Publication date: Available online 26 January 2019

Source: International Journal of Pediatric Otorhinolaryngology

Author(s): Laura Bruneel, Cassandra Alighieri, Sofie De Smet, Kim Bettens, Marc De Bodt, Kristiane Van Lierde

Abstract

Objectives

Recently, the Velopharyngeal Insufficiency (VPI) Effects on Life Outcomes (VELO) questionnaire, which evaluates the impact of speech and swallowing difficulties on health-related quality of life (HRQoL) in patients with VPI (Skirko et al., 2012), was translated to Dutch (Bruneel et al., 2017). The purpose of this study was to evaluate the reproducibility, responsiveness and construct validity of this Dutch version of the questionnaire.

Methods

To evaluate the reproducibility, 50 parents and 14 children with cleft palate re-completed the questionnaire after two weeks. Thirty-five parents and 8 children with cleft palate completed the VELO questionnaire after one year for the evaluation of the responsiveness. The correlation between age and the VELO questionnaire (construct validity), and the internal consistency (Cronbach's α) were re-determined based on the responses of 73 parents and 24 children.

Results

Based on descriptive statistics, results of the Wilcoxon signed rank-test, and the absolute (SEM) and relative (ICC) consistency, the questionnaire showed good reproducibility. VELO scores did not significantly differ after one year, neither when performing separate analyses for the intervention (speech therapy) and the non-intervention group. Correlations indicated higher HRQoL, as perceived by the parents, with increasing age. The reverse was the case for the report. Cronbach's α showed excellent internal consistency for both reports.

Conclusions

The VELO questionnaire showed good reproducibility and internal consistency. Moreover, results reconfirmed the age effect on VELO scores. To understand the implications of the results regarding the questionnaire's responsiveness, future research should focus on the identification of factors influencing the patient's evolution in HRQoL.

http://bit.ly/2Rhmdbq

Complete Polysomnographic Parameters In Infants With Severe Laryngomalacia Prior To And After Supraglottoplasty. A Pilot Study

Publication date: Available online 26 January 2019

Source: International Journal of Pediatric Otorhinolaryngology

Author(s): Cortes María Cristina, Villamor Perla, González C. de la Torre, Álvarez-Neri Hiram

Abstract

Introduction

Laryngomalacia is the most common congenital laryngeal anomaly. Because of supraglottic prolapse, laryngomalacia may be associated with obstructive sleep apnea (OSA) and sleep disturbances. The effects of OSA and sleep disorders in children include failure to thrive, cognitive and behavioral disturbances, cardiovascular compromise, and an association with sudden infant death syndrome.

Objective

To evaluate the presence of OSA and sleep disturbances in children with severe laryngomalacia through complete nocturnal polysomnography, as well as to establish the effects of supraglottoplasty in each of the polysomnographic parameters.

Results

Nine infants with severe laryngomalacia were included, all with a complete polysomnographic study prior to and after supraglottoplasty. The average age was 5.5 months. All patients presented an Apnea-Hypopnea Index (AHI) within the range of severe OSA. After supraglottoplasty, a significant reduction in AHI was found, from 34.87±20.34 to 9.44±5.28 after surgery (p: 0.022). Additionally, sleep efficiency had a significant increase, from 21.4% to 56.29% of total sleep time (p: 0.0013). All patients presented a significant decrease in obstructive apnea episodes (p <0.0001), as well as in hypopnea episodes (p: 0.0154). The mean and minimum peripheral oxygen saturation (SpO2) had a significant increase after supraglottoplasty from 88.2% to 94.09% (p: 0.0002), and from 81.01% to 89.33% (p <0.0001), respectively.

Conclusion

Polysomnography (PSG) may provide better surgical sustenance in infants with severe laryngomalacia and OSA, as well as, serving as a monitoring tool of success. However, the surgical decision should not be reduced to polysomnographic results, and a good history and examination remain as the fundamental criteria.

http://bit.ly/2WnR7D1

Simulation-based education to improve emergency management skills in caregivers of tracheostomy patients

Publication date: Available online 25 January 2019

Source: International Journal of Pediatric Otorhinolaryngology

Author(s): Kara Prickett, Anita Deshpande, Heather Paschal, Dawn Simon, Kiran B. Hebbar

Abstract

Introduction

Children with tracheostomies are medically complex and may be discharged with limited and variably trained home nursing support. When faced with emergencies at home, caregivers must often take the lead role in management, and many lack experience with troubleshooting these emergencies prior to initial discharge.

Methods

A high-fidelity simulation-based tracheostomy education program was designed using a programmable mannequin (Gaumard HAL S3004 one-year-old pediatric simulator). At the conclusion of our standard education program, caregivers completed three simulation scenarios: desaturation, mucus plugging, and dislodgement. A trained simulation facilitator graded performance. A self-assessment tool was used to analyze comfort with emergency management at the beginning of training, before and after simulation. Caregivers rated confidence using a 10 cm visual analog scale. All participants completed a post-simulation debriefing session.

Results

39 caregivers completed all three scenarios and returned pre- and post-simulation self-assessments. Mean scores from the caregiver self-assessments increased for all three scenarios, with mean increases of 9.0 mm for desaturation, 16 mm for mucus plugging, and 10 mm for decannulation. Two patterns of responses emerged: caregivers with progressive increase in confidence through training, and caregivers who initially rated confidence highly, and had confidence decrease as the complexity of true emergency management became apparent. All participants found the simulations to be realistic and helpful.

Discussion

High-fidelity simulation training allows for realistic exposure to trach-related emergencies. Many caregivers overestimate their ability to handle emergencies and gain important insight through simulation.

Implications for Practice

Identification of skills and knowledge gaps prior to discharge allows for targeted re-education in emergency management.

http://bit.ly/2RebXkd

An update of spectrum and frequency of GJB2 mutations causing hearing loss in the south of Iran: A literature review

Publication date: Available online 25 January 2019

Source: International Journal of Pediatric Otorhinolaryngology

Author(s): Mahbobeh koohiyan, Amirhossein Ahmadi, Farideh koohian, Shahrzad Aghaei, Beheshteh Amiri, Morteza Hashemzadeh-Chaleshtori

Abstract

Objective

Mutations in the GJB2 gene are a major cause of autosomal recessive non-syndromic HL (ARNSHL) in many populations. Previous studies have estimated the average frequency of GJB2 mutations to be between 16-18% in Iran, but would vary among different ethnic groups. Here, we have taken together and reviewed results from our three previous publications and data from search other published mutation reports to provide a comprehensive collection of data for GJB2 mutations and HL in the south of Iran.

Methods

In all, 447 unrelated families were included and analyzed for the prevalence and type of the GJB2 gene mutations.

Results

Totally, the frequency of GJB2 mutations was found to be 11.5% in the southern provinces studied which is significantly lower than that identified in Northern populations of Iran, and also a southwest to southeast Iranian gradient in the frequency of GJB2 mutations is suggested.

Conclusions

This study highlights the importance of establishing prevalence, based on the local population for screening and diagnostic programs of live births in Iran.

http://bit.ly/2WiS2UZ

Audiometric Findings in Children with Unilateral Enlarged Vestibular Aqueduct

Publication date: Available online 25 January 2019

Source: International Journal of Pediatric Otorhinolaryngology

Author(s): Robert J. Macielak, Jameson K. Mattingly, Ursula M. Findlen, Aaron C. Moberly, Prashant S. Malhotra, Oliver F. Adunka

Abstract

Objective

To evaluate the prevalence of bilateral hearing loss in children with unilateral enlarged vestibular aqueduct (EVA) at a single institution.

Methods

A retrospective case review was performed at a tertiary care pediatric referral center involving children with radiologic findings of unilateral EVA and normal labyrinthine anatomy of the contralateral ear diagnosed via CT and/or MRI. The main outcome measure of interest is the number of patients with unilateral EVA who were diagnosed with bilateral hearing loss.

Results

Sixty-one pediatric patients were identified. The mean audiometric follow-up was 48.2 months (0-150). Three (4.9%) patients with unilateral EVA were noted to have bilateral hearing loss, and this rate was not significantly different (p=1.0) from the rate reported in a comparison group of patients with contralateral hearing loss (6.0%) without an EVA. The pure-tone average (defined as the average dB HL at 500, 1000, 2000, and 4000 Hz) in the group with bilateral hearing loss was 31.3 dB HL in the better hearing ear and 79.6 dB HL in the worse hearing ear, with the difference being statistically significant (p=0.02). In the unilateral EVA patients without contralateral hearing loss (n=56, 91.8%), the PTA was 9.4 dB HL in the better hearing ear and 51.9 dB HL in the worse hearing ear, with the difference being statistically significant (p<0.001). Two patients (3.3%) with unilateral EVA were found to have hearing within normal limits bilaterally. The EVA was ipsilateral to the worse hearing ear in all cases.

Conclusion

The prevalence of bilateral hearing loss in children with unilateral EVA appears to be low. Specifically, it may be no different than the rate of contralateral hearing loss in children with unilateral hearing loss without an EVA. The present report is somewhat different than the previously described prevalence in the literature. This difference could be related to the imaging type and diagnostic criteria used, the patients included, the source of the identified patents, and the overall population of patients studied.

http://bit.ly/2ReleIZ

Are pediatricians and otolaryngologists well prepared to identify early signs of vertical facial growth?

Publication date: Available online 25 January 2019

Source: International Journal of Pediatric Otorhinolaryngology

Author(s): Christian Calvo-Henríquez, Silvia Martins-Neves, Ana Faraldo-García, Alberto Ruano-Ravina, Sofía Rocha, Miguel Mayo-Yáñez, Gabriel Martinez-Capoccioni

Abstract

BACKGROUND

The prevalence of vertical facial growth is very high in the developed world. Most authors agree that mouth breathing is its main cause. Even though care is mainly conducted by odontologists, the professionals who first see these patients are pediatricians and otolaryngologists. The objective of this study is to analyze the ability of pediatricians and otolaryngologists to identify early signs of vertical facial growth among children.

METHODS

60 participant aged 4.1-13.7 years were analyzed subjectively by 9 otolaryngologists, 9 pediatricians and two specialists in dentofacial orthopedics. They were also assessed objectively with cephalometric analysis.

RESULTS

Otolaryngologists showed 34.78% sensitivity, 92.86% specificity and 48.33% efficiency. Pediatricians showed 13.04% sensitivity, 100% specificity and 33.33% efficiency. Using a linear regression model compared against the objective measurements we found a weak positive correlation both for otolaryngologists and pediatricians.

CONCLUSION

The sensitivity was very low for both groups. We believe it is of paramount importance to increase the awareness and the ability of otolaryngologists and pediatricians to recognize signs of disrupt facial growth.

http://bit.ly/2Wt5hCO

Self‐organizing hair peg‐like structures from dissociated skin progenitor cells: New insights for human hair follicle organoid engineering and Turing patterning in an asymmetric morphogenetic field

Abstract

Human skin progenitor cells will form new hair follicles, although at a low efficiency, when injected into nude mouse skin. To better study and improve upon this regenerative process, we developed an in vitro system to analyze the morphogenetic cell behavior in detail and modulate physical‐chemical parameters to more effectively generate hair primordia. In this three‐dimensional culture, dissociated human neonatal foreskin keratinocytes self‐assembled into a planar epidermal layer while fetal scalp dermal cells coalesced into stripes, then large clusters, and finally small clusters resembling dermal condensations. At sites of dermal clustering, subjacent epidermal cells protruded to form hair peg‐like structures, molecularly resembling hair pegs within the sequence of follicular development. The hair peg‐like structures emerged in a coordinated, formative wave, moving from periphery to center, suggesting that the droplet culture constitutes a microcosm with an asymmetric morphogenetic field. In vivo, hair follicle populations also form in a progressive wave, implying the summation of local periodic patterning events with an asymmetric global influence. To further understand this global patterning process, we developed a mathematical simulation using Turing activator‐inhibitor principles in an asymmetric morphogenetic field. Together, our culture system provides a suitable platform to 1) analyze the self‐assembly behavior of hair progenitor cells into periodically arranged hair primordia, and 2) identify parameters that impact the formation of hair primordia in an asymmetric morphogenetic field. This understanding will enhance our future ability to successfully engineer human hair follicle organoids.

This article is protected by copyright. All rights reserved.

http://bit.ly/2FMVT81

Sonophotocatalytic treatment of rhodamine B using visible-light-driven CeO 2 /Ag 2 CrO 4 composite in a batch mode based on ribbon-like CeO 2 nanofibers via electrospinning

Abstract

CeO₂/Ag₂CrO₄ composite photocatalyst was successfully fabricated using electrospinning and calcination and chemical precipitation method based on CeO₂ ribbon-like fibers and characterized by field-emission scanning electron microscopy (FESEM), energy dispersive X-ray (EDX), X-ray diffraction (XRD), UV–Vis diffuse reflectance spectroscopy (DRS) and Fourier-transform infrared spectroscopy (FT-IR). The as-obtained CeO₂/Ag₂CrO₄ composite used photocatalytic performance in the sonophotodegradation of rhodamine B in aqueous solution under visible-light (LED) irradiation. DRS analysis illustrates that CeO₂/Ag₂CrO₄ composite exhibited enhanced absorption in the visible region-attributed CeO₂ nanofibers_. The effect of four effective parameters including initial concentration of rhodamine B (RhB), photocatalyst dosage, pH, and irradiation time was studied and optimized using central composite design. The kinetic studies confirmed ability of pseudo first-order reaction based on the Langmuir–Hinshelwood model for fitting empirical data, while its rate constant (k_obs), L–H rate constants (k_r), and L–H adsorption constants (K_A) were 0.0449 min⁻¹, 11.66 mg L⁻¹ min⁻¹ and 1.09E−3 mg L⁻¹, respectively. The enhanced photocatalytic activity could be ascribed to the ultrasound field and formation of a heterojunction system among CeO₂ and Ag₂CrO₄, which lead to a better mass transfer and higher efficiency of charge electron–hole separation, respectively.

http://bit.ly/2B5hBA5

Chironomid genera distribution related to environmental characteristics of a highly impacted basin (Argentina, South America)

Abstract

The objective of the present study was to investigate the responses of the chironomid communities (Diptera: Chironomidae) to environmental variables in four moderately and highly disturbed rivers located in one of the most degraded watersheds in South America. Sampling campaigns were carried out during 2014–2016 in four sites of the Matanza-Riachuelo basin. The physical-chemical and hydrological variables were measured and, the ecological indices were calculated and evaluated by ANOVA. The responses of Chironomidae to the environmental variables were evaluated by redundancy analysis (RDA), and the sampling sites were grouped according to the populations of chironomids and the main environmental variables. Finally, the Spearman correlation was made to determine which of these variables were significant. In total, 13 chironomid taxa were found in 36 samples during the study period. The greatest density registered belongs to Rheotanytarsus and Cricotopus. The ANOVA detected the greatest Chironomidae density and taxonomic richness in the sites with agricultural-urban impact. The changes in the distribution of Rheotanytarsus, Thienemanniella, and Polypedilum were mainly explained by the increase in current velocity, organic matter, and hardness, and the decrease of NH3 and BOD. On the other hand, Goeldichironomus, Chironomus, Parachironomus, Dicrotendipes, and Cricotopus were explained by the increase in conductivity, dissolved oxygen, and temperature, and the decrease of the variables NO3, BOD, and Cu. In addition to this, the sites with urban-agricultural impact were clearly separated from sites with urban-industrial impact. The last one was more related to the increase in BOD, Cu, and NO3 that indicates moderate to poor water quality. In conclusion, we can infer that the physical and chemical variables are correlated with changes in the structure and distribution of the chironomid community and there are genera that respond differently at high and intermediate situations of disturbances. This knowledge contributes to the execution of strategies for the conservation and restoration of the lotic ecosystems.

http://bit.ly/2Tgy1fY

The role of unilateral nasal inspiratory peak flow in nasal obstruction‐ a study of seventy patients undergoing septorhinoplasty surgery

Abstract

Nasal Inspiratory Peak Flow (NIPF) poorly correlates with subjective patient reported outcomes (PROMs) following functional septorhinoplasty.

The aim of this study is to determine whether unilateral NIPF correlates with PROMs.

The study demonstrates significant improvement in objective and subjective measurements post septorhinoplasty surgery in seventy patients.

There was weak correlation between improvements in bilateral NIPF when compared with changes in the NOSE score.

Whilst unilateral NIPF does not correlate with subjective outcome scores, it is still a useful measure in assessing nasal patency and in patient education.

This article is protected by copyright. All rights reserved.

http://bit.ly/2DzijY3

Association study of cell cycle proteins and human papillomavirus in laryngeal cancer in Chinese Population

Abstract

Objective

To investigate the role of human papillomavirus (HPV) in laryngeal squamous cell carcinoma (LSCC) and analyze the relationship between HPV and the expression of cell cycle‐related proteins.

Design

The study consisted of LSCC between 2005 and 2011 in Tongren Hospital. Clinical data such as age, sex, smoking/ alcohol consumption and TNM stage were collected. HPV DNA and cell cycle‐related proteins were assessed in terms of clinical features.

Setting

Single center study.

Participants

A total of 332 LSCC patients were included in the study.

Main outcome measures

The presence of genotype‐specific HPV DNA was evaluated using PCR‐RDB in formalin‐fixed paraffin‐embedded tissues. All samples were also evaluated for p16^INK4A, p21^WAF1/CIP1, P53, Cyclin D1, and Ki67 immunohistochemical staining by tissue microarray.

Results

HPV DNA was detected in 45 of 332 (13.55%) patients with LSCC, with HPV‐16 being the predominant genotype. The presence of HPV‐16 DNA was significantly associated with basaloid squamous cell carcinoma and cystic lymph node metastasis (P < 0.05). Of the 332 patients 36 (10.84%) were scored as p16^INK4A positivity, and they were more likely to be female (P < 0.05). Cyclin D1‐positivity and p21^WAF1/CIP1‐positivity were observed in 60.24% (200/332)and 40.66%(135/332), respectively. In 114 cases (34.33%), LSCCs had moderate‐ to ‐strong p53 accumulation, which was correlated with TNM stage (P < 0.05). HPV‐16 DNA was correlated with p16^INK4A, and manifested a higher Ki‐67 labeling index and p21^WAF1/CIP1 expression than HPV‐16‐negative tumors (P < 0.05). No relationship was observed between Cyclin D1or P53 expression and HPV‐16 infection (P > 0.05).

Conclusion

HPV DNA was detected in 13.55% patients with LSCC, with HPV‐16 being the predominant genotype and it was correlated with p16^INK4A, and manifested a higher Ki‐67 labeling index and p21^WAF1/CIP1 expression than HPV‐16‐negative tumors.

This article is protected by copyright. All rights reserved.

http://bit.ly/2UiMSqa

The infraorbital artery: From descriptive anatomy to mucosal perforator flap design

Abstract

Background

The terminal and perforating branches of the infraorbital artery (IOA) are poorly described. Its anatomical situation and mucosal component could provide an interesting donor site for mucosal reconstruction. The aims of the following study were to establish an anatomical description and to assess the feasibility of mucosal perforator flaps for eyelid and nasal reconstruction.

Methods

Twenty‐three fresh cadaver hemifaces were studied in order to perform an IOA anatomical classification by recording the artery's characteristics, its course, number, type, and diameter of terminal branches. We also examined the feasibility of local flaps for facial reconstruction.

Results

We highlighted five different types of courses. All cadavers had at least one superior vestibular branch with a caliber of ≥0.4 mm. A pedicled flap arising from the vestibular branch was raised in all dissections.

Conclusion

The vestibular perforator flap based on the IOA seems to be a reliable flap in reconstruction of mucosal defects.

http://bit.ly/2TftjiB

Tumor implantation following percutaneous endoscopic gastrostomy insertion for head and neck and oesophageal cancer: Review of the literature

Abstract

Background

Because of publication bias, there is uncertainty about the true incidence of tumor seeding or implantation in patients with head and neck or oesophageal cancer undergoing percutaneous endoscopic gastrostomy (PEG) insertion.

Methods

In order to obtain a more reliable estimate of risk, a systematic review was undertaken. Randomized or non‐randomized studies and case reports were identified by electronic searching. A risk of bias assessment was carried out for each study.

Results

Ninety‐eight cases from 74 published case reports and 1 unpublished case were identified. Synchronous distant metastases were present in 37%. Analysis of case series (6192 patients) considered to carry a moderate risk of bias suggests an incidence of seeding after PEG insertion of 0.32%. Studies carrying a lower risk of bias indicate a risk of seeding closer to 1 in 2000.

Conclusion

The true risk of seeding after PEG insertion is probably less than 1 in 1000.

http://bit.ly/2B5fVqh

Detection of laryngeal carcinoma in the U.S. elderly population with gastroesophageal reflux disease

Abstract

Background

An association is suggested between gastroesophageal reflux disease (GERD) or laryngopharyngeal reflux (LPR) and malignancy of the larynx in elderly patients in the United States. Early detection with flexible fiberoptic laryngoscopy (FFL) or CT remains poorly defined.

Methods

The Surveillance, Epidemiology, and End Results (SEER)‐Medicare linked database was queried from 2003 to 2011.A case‐cohort design evaluated patients aged 66 and older with a diagnosis of GERD and/or LPR for the occurrence of FFL or CT within 6 months of the exposure diagnosis.

Results

Of a total 156 426 Medicare beneficiaries, the relative risk of early cancer diagnosis with FFL was 14.61(95% confidence interval [CI], 13.59‐15.70), corresponding to a number needed to detect (NND) a case of cancer of 13(95% CI, 13‐14). The relative risk of an early cancer diagnosis with CT was 31.83 (95% CI, 29.57‐34.26), with a NND of 5 (95% CI, 5‐5).

Conclusions

Early FFL and CT are associated with a higher likelihood of laryngeal cancer diagnosis in elderly individuals with a diagnosis of reflux. Screening trials are necessary to establish this relationship.

http://bit.ly/2ROBeqz

Using the new INTRABEAM mobile intraoperative radiotherapy system during surgery for pancreatic cancer: a case report

Pancreatic cancer is one of the most common fatal malignancies and has a poor prognosis. Surgical treatment is the most important treatment method, but there is a low rate of radical excision; moreover, the po...

http://bit.ly/2CMw2cl

When follow‐up is telling you the truth

Abstract

Over the years, other modified versions of the traditional Mohs surgery have been applied including the perimeter technique (PT). In detail, in our study, the surgical specimen is labeled for margin counting and a further layer including the lesions' bottom is analysed.

This article is protected by copyright. All rights reserved.

http://bit.ly/2WmbrnW

When follow‐up is telling you the truth

Abstract

Over the years, other modified versions of the traditional Mohs surgery have been applied including the perimeter technique (PT). In detail, in our study, the surgical specimen is labeled for margin counting and a further layer including the lesions' bottom is analysed.

This article is protected by copyright. All rights reserved.

http://bit.ly/2WmbrnW

Clinical Trials News

Mon Jan 07, 2019 00:00

Clinical Trials Survey

Would you like to help improve the clinical research experience for patients? We are interested in your opinion about reporting your symptoms for clinical trials. Please click the link below to complete this short, 5-minute survey. Your anonymous responses will be used for research purposes to better understand how to improve patient care. Complete the survey and provide your email address to be entered to win a $100 Visa gift card! Thank you for taking the time to provide your opinion.

ClinicalConnection.com New Clinical Trials

Mon Jan 07, 2019 00:00

Schizophrenia - Princeton NJ

Do you or a loved one suffer from Schizophrenia? If so, Princeton Medical Institute located in Princeton, NJ is conducting a clinical research trial of an investigational treatment for Schizophrenia. We're seeking volunteers 18 to 65 years old who have been diagnosed with Schizophrenia Study-related exams, procedures, and medication are provided at no cost. Visit our website to learn more and submit your interest! Common Symptoms of Schizophrenia May Include: Withdrawal from reality Hallucinations...

ClinicalConnection.com New Clinical Trials

Sun Jan 06, 2019 00:00

Pediatric Plaque Psoriasis - Clearwater FL

Click image to enlargeLocal dermatologists are conducting a clinical research study to test the effectiveness and safety of an investigational topical medication for Plaque Psoriasis.Qualified Participants Must:Be 12-16 years old Provide consent and be accompanied by a legal guardian at the time of consent signing Have an Investigator's Global Assessment (IGA) score of at least 3 Be willing to comply with all study instructions and commit to follow-up visits Females must not be pregnant and agree...

ClinicalConnection.com New Clinical Trials

Fri Jan 04, 2019 00:00

<b>Eczema (Atopic Dermatitis) - Webster TX</b>

Click image to enlarge

ClinicalConnection.com New Clinical Trials

Thu Jan 03, 2019 00:00

<b>ADHD with Impulsive Aggression - Grand Prairie TX</b>

 Aggression refers to a behavior that can result in both physical and psychological harm to oneself, others or objects in the environment. Aggression is manifested verbally, mentally, and physically. Such behavior becomes maladaptive when it persists, occurs outside an acceptable social context, and is of an intensity, frequency, severity and/or duration detrimental to the child's interests. This is a double-blind, randomized, parallel group, two-arm, placebo-controlled study with flexible dosing...

ClinicalConnection.com New Clinical Trials

Thu Jan 03, 2019 00:00

Osteoarthritis of the Knee - La Mesa CA

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Woodstock GA

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Excessive Underarm Sweating Study for Children - Raleigh NC

Does Your Child Struggle with Excessive Underarm Sweat?Consider Joining a Clinical Research Study of a New MedicationWake Research is enrolling participants in a study of an investigational medication for excessive underarm sweat in children and teens.

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Phoenix AZ

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Remove ads

Osteoarthritis of the Knee - Albuquerque NM

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Kansas City MO

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Carmichael CA

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Edgewater FL

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - San Angelo TX

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Charleston SC

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

<b>Osteoarthritis of the Knee - Multiple Locations in the US</b>

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Cincinnati OH

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Alzheimer's Disease - Spring Hill FL

If you are caring for someone with Alzheimer's disease, please consider the ROAD clinical research study, which will determine the safety and effectiveness of the multifunctional small moleculeAD-35 in patients with mild to moderate Alzheimer's disease (AD).Key Eligibility Criteria• Between 50 and 85 years of age (inclusive)• Diagnosed with probable AD in accordance with the National Institute on Aging and Alzheimer's Association (NIA-AA) criteria• Mini-Mental State Examination (MMSE) score of ≥>...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Child ADHD - Lakeland FL

Is your child is experiencing the following symptoms:  trouble staying focused, interrupts others, hyper or impulsive or does not listen, OR has already been diagnosed with Attention Deficit Hyperactivity Disorder (ADHD)? If yes, learn more about a medical research study evaluating an investigational study drug in children 6 to 17 years of age. 

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Data Highlighting Potential Benefits of Lm Platform Presented at 2019 Keystone Symposia Conference on Cancer Vaccines

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that two presentations highlighting the potential of Advaxis vectors to generate T cell responses to a large percentage of neoantigens and to promote antigen spreading and potentially slow progression of prostate cancer, were presented at the 2019 Keystone Symposia on Cancer Vaccines, held January 19-24

Business Wire Health: Clinical Trials News

Fri Jan 25, 2019 15:05

Global PD-1 and PD-L1 Inhibitors Market 2019-2023 | Strong Pipeline to Boost Growth | Technavio

LONDON--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Inhibitors?src=hash" target="_blank"gt;#Inhibitorslt;/agt;--The global PD-1 and PD-L1 Inhibitors market is expected to post a CAGR of over 19% during the period 2019-2023, according to Technavio.

Business Wire Health: Clinical Trials News

Fri Jan 25, 2019 14:00

Circassia to buy US, China marketing rights to AIT's AirNOvent

The acquired rights will cover all potential indications in the hospital setting for the administration of inhaled AirNOvent at up to 80 parts per million. One of the The post Circassia to buy US, China marketing rights to AIT's AirNOvent appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Fri Jan 25, 2019 08:54

Navitor Pharmaceuticals commences phase 1 clinical evaluation of NV-5138 for treatment-resistant depression

NV-5138 is a first-in-class, orally-active small molecule that directly activates mTORC1, the gatekeeper of cellular metabolism and renewal, which is suppressed in the brain of people suffering from The post Navitor Pharmaceuticals commences phase 1 clinical evaluation of NV-5138 for treatment-resistant depression appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Fri Jan 25, 2019 08:54

FDA accepts X-Rx's IND application for X-165 to treat IPF

X-165 is a highly potent and selective small molecule inhibitor of Autotaxin owned by X-Rx. An initial advanced lead series that led to the identification of X-165 was The post FDA accepts X-Rx's IND application for X-165 to treat IPF appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Fri Jan 25, 2019 08:54

EC approves Clovis' Rubraca to treat women with relapsed ovarian cancer

The second indication of Rubraca has been approved as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer The post EC approves Clovis' Rubraca to treat women with relapsed ovarian cancer appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Fri Jan 25, 2019 06:56

ImmunoGen Announces Conference Call to Discuss Its 2018 Operating Results

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 8, 2019 to discuss its 2018 operating results. Management will also provide a brief update on the business. Conference Call InformationTo access the live call by phone, dial 323-794-2093; the conference ID is 6271602. The call may also be a

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 23:30

Immunomic to Present at the 2019 BIO CEO & Investor Conference

ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that its' founder and CEO, William Hearl, Ph.D., will present an overview of the company and its UNITE technology platform at the 2019 BIO CEO & Investor Conference on February 12, 2019 at 2:00 pm EST in the Hudson/Empire Room at the Marriott Marquis in New York City. About UNITE ITI's investigational UNITE platform, or UNiversal Intracellular Targeted Expression, is thought to work by encoding the Lysosomal Assoc

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 23:05

Vermont Collaborative Partners with Netsmart to Alter Trajectory of Care for State's Most Vulnerable

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Four member agencies of Vermont Care Partners (VCP) have come together to reshape the delivery and coordination of care through a partnership with Netsmart to deploy a unified technology platform. As value-based care quickly becomes reality, Lamoille County Mental Health Services, Northwestern Counseling and Support Services, United Counseling Services of Bennington and Washington County Mental Health Services will leverage the full suite of solutions from

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 22:00

Remove ads

Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study

The treatment of patients with Bing-Neel syndrome (BNS) is not standardized. We included patients with Waldenström macroglobulinemia (WM) and a radiologic and/or cytologic diagnosis of BNS treated with ibrutinib monotherapy. Response assessment was based on criteria for BNS from the 8th International Workshop for WM. Survival from BNS diagnosis (BNS survival), survival from ibrutinib initiation to last follow-up or death (ibrutinib survival), and time from ibrutinib initiation to ibrutinib discontinuation...

Blood CLINICAL TRIALS AND OBSERVATIONS

Thu Jan 24, 2019 19:00

Oyster Point Pharma to Present at the BIO CEO & Investor Conference

PRINCETON, N.J.--(BUSINESS WIRE)--Oyster Point Pharma to present a corporate overview at the BIO CEO & Investor Conference.

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 17:33

Midwest Vision Research Foundation at Pepose Vision Institute Joins the AcuFocus IC-8® Lens Clinical Study for Patients with Cataracts

ST. LOUIS, Mo.--(BUSINESS WIRE)--Midwest Vision Research Foundation at Pepose Vision Institute joins the AcuFocus IC-8® Lens clinical study for cataracts.

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 16:05

Tamr Joins Accenture's Life Sciences Ecosystem to Help Drive Innovation in Drug Discovery and Scientific Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tamr Inc. today announced it has joined Accenture's open partner ecosystem, designed to help independent software vendors (ISVs) and life science companies team more effectively to accelerate drug discovery efforts and improve patient outcomes. The ecosystem is an integral part of Accenture's cloud-based informatics research platform, which has been designed to help life sciences organizations improve productivity, efficiency, and innovation in drug discovery.

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 16:00

Gamida Cell Announces Data from NAM-NK and NiCord® Programs to Be Presented at 2019 TCT Annual Meeting

BOSTON--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24GMDA&src=ctag" target="_blank"gt;$GMDAlt;/agt;--Gamida Cell announces data from NAM-NK and NiCord® programs to be presented at 2019 TCT Annual Meeting

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 15:32

X-Rx Announces FDA Acceptance of IND Application for X-165

WALTHAM, Mass.--(BUSINESS WIRE)--X-Rx Announces FDA Acceptance of IND Application for X-165

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 15:15

Can-Fite BioPharma CEO Letter to Shareholders

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that Pnina Fishman, Chief Executive Officer of Can-Fite Biopharma, has issued a Letter to Shareholders, the full text of which follows below. Dear Can-Fite Shareholders, It has been a very busy and productive year at Can Fite BioPharma, filled with c

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:30

Dicerna Evolves Its Board of Directors to Support Continued Growth

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna announced several changes to its board of directors, reflecting the company's ongoing growth.

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:30

Basilea Announces Collaboration to Study Derazantinib and Atezolizumab (Tecentriq®) in Urothelial Cancer

BURLINGTON, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24ARQL&src=ctag" target="_blank"gt;$ARQLlt;/agt; lt;a href="https://twitter.com/hashtag/arql?src=hash" target="_blank"gt;#arqllt;/agt;--ArQule, Inc.'s (Nasdaq: ARQL) partner, Basilea Pharmaceutica Ltd. (SIX: BSLN), announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore a combination of derazantinib (BAL087) and Roche's PD-L1-blocking immune-checkpoint inhibitor, atezolizumab (Tecentriq®),...

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:00

Concert Pharmaceuticals Initiates Phase 1 Single-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia

LEXINGTON, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24CNCE&src=ctag" target="_blank"gt;$CNCElt;/agt; lt;a href="https://twitter.com/hashtag/CNCE?src=hash" target="_blank"gt;#CNCElt;/agt;--Concert began a Phase 1 single-ascending dose trial to evaluate the safety, tolerability, and PK profile of CTP 692 in healthy volunteers.

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:00

Navidea Biopharmaceuticals Announces Decision by Ohio Supreme Court

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the Ohio Supreme Court has dismissed a Petition filed by Capital Royalty Partners II, L.P. and affiliated entities. On August 27, 2018, Capital Royalty Partners II, L.P. and several affiliated entities ("CRG") filed a Petition with the Ohio Supreme Court seeking a

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:00

Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results

NEW YORK--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24BMY&src=ctag" target="_blank"gt;$BMYlt;/agt;--Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 13:59

BridgeBio Pharma raises $299.2m in financing round

BridgeBio Pharma will also use the funds to expand its efforts on the development of medicines for patients with unmet needs. Both existing investors KKR and Viking Global The post BridgeBio Pharma raises $299.2m in financing round appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Thu Jan 24, 2019 13:17

Ironwood Pharmaceuticals initiates phase 1 trial of IW-6463

Data from the Phase 1 study are expected in the second half of 2019. "The initiation of this Phase 1 study with IW-6463 marks an important milestone for The post Ironwood Pharmaceuticals initiates phase 1 trial of IW-6463 appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Thu Jan 24, 2019 11:20

BioNTech to acquire MAB Discovery's antibody generation unit

Under the terms of the agreement, BioNTech will acquire all assets, employees and proprietary know-how for mAb generation from MAB Discovery. MAB Discovery will retain ownership of and The post BioNTech to acquire MAB Discovery's antibody generation unit appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Thu Jan 24, 2019 13:17

ChemoCentryx Announces Withdrawal of Phase II-Based Conditional Marketing Authorisation (CMA) Application for ANCA-Associated Vasculitis in Europe, Phase III Advocate Trial Data Release Planned for Q4 2019

ZURICH & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Regulatory News: ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma Ltd., a company of Vifor Pharma Group, today announced that in light of the upcoming availability of data from the pivotal Phase III ADVOCATE trial – the largest controlled trial in active anti-neutrophil cytoplasmic antibody associated vasculitis (ANCA-associated vasculitis) – they have decided to withdraw the application for Conditional Marketing Authorisation (CM

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 08:00

Gossamer Bio Announces Commencement of Initial Public Offering

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") in connection with the commencement of a proposed initial public offering of its common stock. Gossamer Bio is offering 14,375,000 sha

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 00:24

Advaxis' Phase 3 AIM2CERV Study Placed on Partial Clinical Hold by FDA Related to CMC Requests

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced receipt of notification from the U.S. Food and Drug Administration (FDA) that the Company's ongoing Phase 3, randomized, double-blinded, placebo-controlled, pivotal study of axalimogene filolisbac (AXAL) in high-risk, locally advanced cervical cancer (AIM2CERV) has been placed on partial clinical

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 23:05

Ironwood Pharmaceuticals Initiates Phase 1 Trial of IW-6463, the First CNS-penetrant sGC Stimulator to Enter Clinical Trials

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced the initiation of a Phase 1 study evaluating IW-6463 in healthy volunteers. IW-6463 is an orally administered central nervous system (CNS)-penetrant soluble guanylate cyclase (sGC) stimulator that is being developed for the treatment of serious and orphan CNS disorders. Data from the Phase 1 study are expected in the second half of 2019. "The initiation of this Phase 1 study with IW-6463 marks an im

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 23:01

Vedanta Biosciences Announces Publication in Nature of Seminal Research Revealing A New Mechanism of Human Microbiota-Driven Antitumor Immunity Involving Induction of IFNy+ CD8+ T Cell Accumulation in the Gut and Tumors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences announced a publication in Nature that revealed a newly discovered mechanism underlying antitumor immunity.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 20:07

Remove ads

Modulated Imaging Raises $7M in Series B Funding

IRVINE, Calif.--(BUSINESS WIRE)--Modulated Imaging has raised $7 million in Series B funding to fund the commercialization of its Clarifi technology and clinical studies.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 19:30

Vascular Dynamics Names Prof. Martin Rothman Chief Medical Officer

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--World-renowned interventional cardiologist Martin Rothman has been named chief medical officer at VDI.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 19:05

Redx gets regulatory nod to restart RXC004 clinical trial

An oral porcupine inhibitor, RXC004 has been designed to target the Wnt signaling pathway. The early-stage trial of the small molecule drug was temporarily stopped in March 2018 The post Redx gets regulatory nod to restart RXC004 clinical trial appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Wed Jan 23, 2019 17:43

U.S. Patent Office Issues CEL-SCI Two Patents for Its LEAPS Vaccine Platform Technology

VIENNA, Va.--(BUSINESS WIRE)--U.S. patent office issues CEL-SCI two patents for its LEAPS vaccine platform technology.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 16:20

Medidata Joins the World Economic Forum

NEW YORK--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/MDSO?src=hash" target="_blank"gt;#MDSOlt;/agt;--Medidata (NASDAQ:MDSO) today announced that it has entered into a three-year strategic collaboration with the World Economic Forum. The company becomes a Partner Member Associate and will participate in the WEF System Initiative focused on Shaping the Future of Health and Healthcare. The initiative has a goal of transforming the continuum of care – from prevention to diagnosis, treatment,...

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 15:30

Ferring Pharmaceuticals appoints Sophie Opdyke to lead its new U.S. oncology division

PARSIPPANY, N.J.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Ferring?src=hash" target="_blank"gt;#Ferringlt;/agt;--Sophie Opdyke, Pharm.D., MBA, will be responsible for building the Ferring Pharmaceuticals (U.S.) oncology division

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 15:25

InGeneron Expands Development Pipeline with Two Osteoarthritis Programs

HOUSTON--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/backpain?src=hash" target="_blank"gt;#backpainlt;/agt;--InGeneron expands development pipeline with two studies for chronic backpain and wrist osteoarthritis, setting focus on orthopedic indications.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 15:00

BridgeBio Pharma Closes $299.2 Million Financing Round to Support Its Efforts to Target Genetic Disease at the Source

PALO ALTO, Calif.--(BUSINESS WIRE)--BridgeBio Pharma, a clinical-stage biopharmaceutical company focused on genetic diseases, today announced a new financing round of $299.2 million. The round was co-led by existing investors KKR and Viking Global Investors. Other existing investors participating included Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital, and Hercules Capital; and they were joined by new investors Sequoia Capital, and a blue-chip long-term investor. The financing wil

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 15:00

Talee Bio Announces $4.5 Million Award from the Cystic Fibrosis Foundation to Advance Development of Two Gene Therapy Product Candidates

PHILADELPHIA--(BUSINESS WIRE)--Talee Bio, Inc., a development stage biopharmaceutical company focused on developing gene therapy treatments for cystic fibrosis, today announced agreements with the Cystic Fibrosis Foundation (CF Foundation) to fund the preclinical development of two mutation-agnostic gene therapy product candidates, TL-101 and TL-102. The CF Foundation committed up to $4.5 million to expedite the development of both product candidates for all people with cystic fibrosis, and par

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 14:00

Sage Therapeutics Appoints Elizabeth Barrett and George Golumbeski to Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the addition of Elizabeth (Liz) Barrett and George Golumbeski, Ph.D., to the company's board of directors. "We are extremely pleased to add these two experienced executives to Sage's board of directors. As Sage continues to advance its programs in development, adding an executive

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 14:00

Triumvira Announces Build out of Senior Management Team with Addition of Industry-Experienced Professionals in R&D and Business Development

AUSTIN, Texas & HAMILTON, Ontario--(BUSINESS WIRE)--Triumvira appoints Andreas Bader as Senior Vice President of Research & Development and Joshua Carle as Vice President of Business Development.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 14:00

New Study Shows Supplementation with Nicotinamide Riboside (NR) During Breastfeeding Yields Measurable, Lasting Benefits to Mothers and Offspring in Animal Model

LOS ANGELES--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Breastfeeding?src=hash" target="_blank"gt;#Breastfeedinglt;/agt;--Supplementation with unique B3 vitamin nicotinamide riboside confers significant and enduring physiological benefits to mouse mothers and offspring.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 13:30

Idiopathic Pulmonary Fibrosis Report - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019-2021 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Idiopathic Pulmonary Fibrosis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Idiopathic Pulmonary Fibrosis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Idiopathic Pulmonary Fibrosis . The report includes information of marketed products including their product des

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 13:24

EC approves Blincyto in patients with Philadelphia chromosome negative minimal residual disease-positive B-cell precursor ALL

The approval was based on data from the Phase 2 BLAST study in frontline and relapsed/refractory ALL, the largest prospective trial for MRD-positive ALL ever conducted. BLINCYTO, a The post EC approves Blincyto in patients with Philadelphia chromosome negative minimal residual disease-positive B-cell precursor ALL appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Wed Jan 23, 2019 11:52

Rocket Pharmaceuticals announces clearance of IND for RP-A501 gene therapy for Danon disease

RP-A501 is the Company's first adeno-associated viral vector (AAV)-based gene therapy for the treatment of Danon disease that is in development under a collaboration with the University of The post Rocket Pharmaceuticals announces clearance of IND for RP-A501 gene therapy for Danon disease appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Wed Jan 23, 2019 11:52

GSK closes acquisition of Tesaro for $5.1bn

Tesaro acquisition will enable GSK to strengthen its pharmaceutical business; and expand its pipeline and commercial capability in oncology. Tesaro president and COO Dr Mary Lynne Hedley said: The post GSK closes acquisition of Tesaro for $5.1bn appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Wed Jan 23, 2019 11:52

UroGen Pharma Announces Proposed Public Offering of Ordinary Shares

NEW YORK--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it intends to offer and sell $150 million of its ordinary shares in an underwritten public offering. The company also intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of ordinary shares sold in the offering at the pu

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 23:01

LabCorp Named to FORTUNE Magazine's 2019 List of 'World's Most Admired Companies,' Making the Annual List for the Second Consecutive Year

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp® (NYSE: LH), a leading global life sciences company, today announced that it has been named to FORTUNE magazine's 2019 List of World's Most Admired Companies, making the annual list for the second consecutive year. The annual survey, conducted by FORTUNE and Korn Ferry, a global organizational consulting firm, is given to top executives, directors, and financial analysts to identify the companies that enjoy the strongest reputations within their indust

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 17:35

Gamida Cell and Be The Match BioTherapies® Announce Strategic Collaboration

BOSTON & MINNEAPOLIS--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24GMDA&src=ctag" target="_blank"gt;$GMDAlt;/agt;--Gamida Cell and Be The Match BioTherapies® announced a collaboration to improve outcomes for patients undergoing bone marrow transplantation.

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:30

Bio-Thera Solutions Announces Initiation of Phase III Clinical Trial for BAT1806, a Proposed Biosimilar of Actemra® (Tocilizumab)

GUANGZHOU, China--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/arthritis?src=hash" target="_blank"gt;#arthritislt;/agt;--Bio-Thera Solutions announces the initiation of a Phase III clinical trial for BAT1806, a proposed biosimilar of Actemra® (Tocilizumab).

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:08

Remove ads

LabConnect Announces Global Sample Processing Network

SEATTLE--(BUSINESS WIRE)--LabConnect is pleased to announce a new service: LabConnect's global sample processing network (GSPN).

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:00

Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2018 Financial Results on February 7, 2019

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and full year 2018 financial results on Thursday, February 7, 2019 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Thursday, February 7, 20191:30 p.m. Pacific Time / 4

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:00

Rainier Therapeutics Announces Oral Abstract Presentation on Fierce 21 Phase 2 Trial of Vofatamab in Metastatic Urothelial Cell Carcinoma (Bladder Cancer) at the 2019 ASCO Genitourinary Cancers Symposium

SAN LEANDRO, Calif.--(BUSINESS WIRE)--Data from ongoing P2 trial of Rainier's FGFR3-targeted antibody vofatamab to be presented at 2019 ASCO Genitourinary Cancers Symposium Feb 14 in SF

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:00

Resumen: Gore presenta en Europa la endoprótesis para aorta torácica adaptable GORE® TAG® con perfiles reducidos

FLAGSTAFF, Arizona--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) ha introducido hoy perfiles reducidos para los diámetros más utilizados de la endoprótesis para aorta torácica adaptable GORE® TAG® con el sistema de CONTROL ACTIVO. El perfil reducido permite a los médicos realizar reparaciones endovasculares torácicas (TEVAR) en pacientes con vasos más pequeños donde el acceso es difícil y la anatomía aórtica es tortuosa, lo que amplía la disponibilidad de la endoprótesis para aorta

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:47

Samenvatting: Gore introduceert GORE® TAG® Conformable Thoracic Stent Graft met gereduceerde profielen in Europa

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) introduceerde vandaag gereduceerde profielen voor de meest gebruikte diameters van de GORE® TAG® Conformable Thoracic Stent Graft met ACTIVE CONTROL System. Het gereduceerde profiel stelt artsen in staat om TEVAR uit te voeren bij patiënten met kleinere vaten waar de toegang moeilijk is en de aorta anatomie kronkelig is, waardoor de beschikbaarheid van Gore's thoracale stenttransplantaat wordt uitgebreid naar een groter

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:47

Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Chronic Graft-Versus-Host Disease

WILMINGTON, Del.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24INCY&src=ctag" target="_blank"gt;$INCYlt;/agt;--Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Chronic Graft-Versus-Host Disease

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:30

Data Presented at LINC Confirm the Safety and Effectiveness of Zilver® PTX®

BLOOMINGTON, Ind.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/cookmedical?src=hash" target="_blank"gt;#cookmedicallt;/agt;--Today at the Leipzig Interventional Course (LINC), Cook Medical participated in significant discussion about the use of paclitaxel to treat patients suffering from PAD. Through several presentations to meeting attendees, data supported the use of paclitaxel-coated devices to help the more than 200 million1 patients globally who are fighting the disease. "We believe...

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:10

Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced positive results for its exploratory Phase 2 head-to-head study evaluating the efficacy, safety and tolerability of voclosporin ophthalmic solution (VOS 0.2%) versus Restasis®(cyclosporine ophthalmic emulsion 0.05%) for the treatment of dry eye syndrome (DES). Both drugs were shown to be well-tolerate

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:00

Concert Pharmaceuticals Completes Enrollment of 12 mg Cohort in Phase 2a Trial of CTP-543 in Alopecia Areata

LEXINGTON, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24CNCE&src=ctag" target="_blank"gt;$CNCElt;/agt; lt;a href="https://twitter.com/hashtag/AlopeciaAreata?src=hash" target="_blank"gt;#AlopeciaAreatalt;/agt;--Concert completed enrollment in its Phase 2a trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata.

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:00

Immunochina Raises $20.4 Million USD in Series C Financing

BEIJING--(BUSINESS WIRE)--Beijing-based Immunochina Pharmaceuticals today announced the closing of its $140 million RMB Series C financing (approximately $20.4 million in US Dollars). This financing will enable the company to expand its GMP-grade manufacturing capabilities while continuing clinical trials for its lead IM19 product targeting B-Cell Acute Lymphoblastic Leukemia (B-ALL) and Non Hodgkin's Lymphoma, as well as advancing the development of its pipeline targeting multiple solid and li

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:00

Aplastic Anemia - Pipeline Insight, 2019 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Aplastic Anemia - Pipeline Insight, 2019" drug pipelines report has been added to ResearchAndMarkets.com's offering. This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Aplastic Anemia development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, assoc

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 13:40

Cluster Headache Syndrome - Pipeline Insight, 2019 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Cluster Headache Syndrome - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Cluster Headache Syndrome development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 13:34

TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy products

GLASGOW, Scotland--(BUSINESS WIRE)--TC BioPharm (TCB), a developer of CAR-T immuno-oncology products, including Gamma Delta T (GDT) cell therapies, today announced it has completed formulation of its first allogeneic GDT cell banks. The T cell banks provide TCB with core technology to develop a deep portfolio of next-generation CAR-T products directed against a wide variety of different cancer types, both hematological and solid tumors. The project was supported by funding from the European Uni

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 12:55

Rationale and study design of the MyHEART study: A young adult hypertension self-management randomized controlled trial

Publication date: Available online 21 January 2019Source: Contemporary Clinical TrialsAuthor(s): Heather M. Johnson, Lisa Sullivan-Vedder, KyungMann Kim, Patrick E. McBride, Maureen A. Smith, Jamie N. LaMantia, Jennifer T. Fink, Megan R. Knutson Sinaise, Laura M. Zeller, Diane R. LauverAbstractYoung adults (18–39 year-olds) with hypertension have a higher lifetime risk for cardiovascular disease. However, less than 50% of young adults achieve hypertension control in the United States. Hypertension...

ScienceDirect Publication: Contemporary Clinical Trials

Tue Jan 22, 2019 13:13

EC approves Vertex's CF treatment Orkambi for children aged two to five years

The label extension has been granted to treat the most common form of CF based on data from a phase 3 open-label safety study in 60 patients. According The post EC approves Vertex's CF treatment Orkambi for children aged two to five years appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Tue Jan 22, 2019 12:25

Nash's NASH NP-160 shows repeated positive results in second pre-clinical study

In addition, a second compound, NP-135 was identified as an additional lead. Both NP-135 and NP-160 are one of a number of already approved compounds that Nash has The post Nash's NASH NP-160 shows repeated positive results in second pre-clinical study appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Tue Jan 22, 2019 12:25

Global Clinical Trials 2007-2018: Current Trends and Recent Advancements - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Clinical Trials - Current Trends and Recent Advancement" report has been added to ResearchAndMarkets.com's offering. "Global Clinical Trials Current Trends and Recent Advancement", provides an in-depth assessment of the current trends in the number of clinical trials globally, Top 10 therapy area, geography wise clinical trials, YOY clinical trials in top 10 therapy area. An overview of clinical guidelines reforms has also been provided to show how regulator

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 11:17

PredictImmune Confirms Canadian Patent Grant

CAMBRIDGE, England--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/IBD?src=hash" target="_blank"gt;#IBDlt;/agt;--PredictImmune confirm Canadian patent grant which covers PredictImmune's intellectual property relating to methods for predicting autoimmune disease

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 11:00

PCI announces further investment in infrastructure for packaging of controlled substances

PCI has extended onsite controlled substance storage at its US commercial packaging locations in Philadelphia, PA and Rockford, IL, and will undertake further expansions as demand increases for The post PCI announces further investment in infrastructure for packaging of controlled substances appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Tue Jan 22, 2019 12:25

Remove ads

Wren Therapeutics Completes £18 Million Series A Financing

CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Wren Therapeutics ("Wren"), a biopharmaceutical company focused on drug discovery and development for protein misfolding diseases, today announces it has completed a Series A financing round. The company, formally founded in 2016, raised a total of £18 million from an international syndicate led by The Baupost Group with participation from LifeForce Capital and a number of high net worth individual investors. Protein molecules form the machinery that

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 09:30

EMMAC Life Sciences PLC: Acquisition of a Majority Interest in Medalchemy, a GMP Certified Laboratory, in Alicante Spain

LONDON--(BUSINESS WIRE)--EMMAC, the European independent medical cannabis company, is pleased to announce the acquisition of a majority interest in Medalchemy, a fully-licensed GMP certified laboratory in Alicante, Spain. Medalchemy, a technology-based manufacturing company located on the premises of the University of Alicante, has more than a decade of experience in the research, development and manufacture of active pharmaceutical ingredients (APIs) and has submitted license applications to i

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 09:00

Updated Analysis of Pivotal Study Reveals: Proactive, High Dosage of Venofer® Significantly Reduces Risk of Death or Major Cardiovascular Events in Haemodialysis Patients

ZURICH--(BUSINESS WIRE)--Re-analysis of pivotal study reveals: Proactive, High DOSAGE OF venofer®...

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 08:00

Ferring, Rebiotix and Karolinska Institutet Extend Collaboration to Research Next Generation of Microbiome Treatments

SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals and Karolinska Institutet announced today a five-year extension of their collaboration to explore the potential of the human microbiome in reproductive medicine and women's health and gastroenterology. The collaboration brings together specialist expertise from Karolinska Institutet in early stage research, Rebiotix Inc. (acquired by Ferring in 2018), a late-stage clinical microbiome company, and Ferring's therapeutic area and co

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 08:00

Proteus Digital Health Launches Digital Oncology Medicines to Improve Patient Outcomes

January 17, 2019 – REDWOOD CITY, Calif. and MINNEAPOLIS, Minn. – Proteus Digital Health®, Inc., Fairview Health Services, and University of Minnesota Health announced today that for the first time cancer patients are using digital...

Drugs.com - Clinical Trials

Thu Jan 17, 2019 22:01

Two Positive Phase III studies of Tafenoquine for the Radical Cure of Plasmodium vivax Malaria Published in The New England Journal of Medicine

London UK; Philadelphia US; Geneva Switzerland - January 16, 2019 -- GSK and Medicines for Malaria Venture (MMV) today announced the publication of positive results from two phase III studies of single-dose tafenoquine for the radical cure...

Drugs.com - Clinical Trials

Wed Jan 16, 2019 23:01

vTv Therapeutics Announces Publication of Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study

HIGH POINT, N.C.--(BUSINESS WIRE)--Jan. 16, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the publication of a paper in Science Translational Medicine showcasing the discovery and development of TTP399, an investigational, oral, small...

Drugs.com - Clinical Trials

Wed Jan 16, 2019 22:01

Amgen Makes All Repatha (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price

THOUSAND OAKS, Calif., Jan. 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that as part of the Company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at...

Drugs.com - Clinical Trials

Mon Jan 07, 2019 22:01

Gore führt GORE® TAG® Conformable Thoracic Stent Graft mit reduzierten Profilen für die Vermarktung in Europa ein

FLAGSTAFF, Arizona--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) meldete heute die Markteinführung reduzierter Profile für die am häufigsten verwendeten Durchmesser von GORE® TAG® Conformable Thoracic Stent Graft mit ACTIVE CONTROL System. Das reduzierte Profil ermöglicht es den Ärzten, bei Patienten mit kleineren Blutgefäßen eine thorakale endovaskuläre Aortenreparatur (TEVAR) durchzuführen, wenn der Zugang anspruchsvoll und die Aorta gewunden ist, um auf diese Weise die Einsatzmö

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 22:37

Gore lance sur le marché européen GORE® TAG®, une endoprothèse thoracique conformable à profils réduits

FLAGSTAFF, Arizona--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) a présenté aujourd'hui des profils réduits des diamètres les plus couramment utilisés de l'endoprothèse thoracique conformable implantable GORE® TAG® dotée du système ACTIVE CONTROL. La réduction du profil permet aux médecins de procéder à une procédure TEVAR (réparation endovasculaire des anévrismes de l'aorte thoracique) chez les patients dont les vaisseaux sont étroits et difficiles d'accès et l'anatomie aortique t

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 19:30

Riassunto: Gore lancia in Europa lo stent graft toracico conformabile GORE® TAG® con profili ridotti

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) ha oggi lanciato profili ridotti per i diametri più comunemente utilizzati dello stent graft toracico conformabile GORE® TAG® con sistema ACTIVE CONTROL. Il profilo ridotto consente al personale medico di eseguire trattamenti endovascolari dell'aorta toracica (TEVAR) nei pazienti con vasi sanguigni più piccoli, di difficile accesso e con anatomia aortica tortuosa, ampliando la disponibilità dello stent graft toracico di

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 16:18

Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 14:00

Vertex Announces European Commission Approval for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. "Today's approval by the European Commission brings us one step closer to our goal of bringing treatment to all people living with CF," said Reshma K

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 11:00

Gore Introduces GORE® TAG® Conformable Thoracic Stent Graft with Reduced Profiles in Europe

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--Gore Introduces GORE® TAG® Conformable Thoracic Stent Graft with Reduced Profiles in Europe

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 10:00

Promentis Pharmaceuticals commences phase 2 studies for SXC-2023 targeting Glutamatergic mechanism

Promentis is developing SXC-2023 along with other compounds that engage System xc-, a central nervous system target addressing glutamatergic imbalance and oxidative stress, to treat trichotillomania and other The post Promentis Pharmaceuticals commences phase 2 studies for SXC-2023 targeting Glutamatergic mechanism appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Mon Jan 21, 2019 12:58

Kyn Therapeutics, Celgene partner on immuno-oncology therapies development

The collaboration will combine the immuno-oncology expertise and pipeline of Kyn Therapeutics with the capabilities of Celgene in development and commercialization of drugs in areas of high unmet The post Kyn Therapeutics, Celgene partner on immuno-oncology therapies development appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Mon Jan 21, 2019 09:02

Lilly's second immune-oncology candidate using Zymeworks' Azymetric platform to start clinical trials

In accordance with Zymeworks' 2014 licensing and collaboration agreement with Lilly, Zymeworks will receive a milestone payment of US$8.0 million for Lilly's submission of an IND application for The post Lilly's second immune-oncology candidate using Zymeworks' Azymetric platform to start clinical trials appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Mon Jan 21, 2019 12:58

SanBio: Addition of a Cerebral Hemorrhage Program for SB623 Regenerative Cell Medicine

TOKYO--(BUSINESS WIRE)--At a meeting held today, the Board of Directors of SanBio Co., Ltd. (hereinafter, the "Company") resolved to add a program for treatment of chronic motor deficit from cerebral hemorrhage as a new indication for SB623, a regenerative cell medicine developed by the Group. (Hereinafter, the "Group" refers to two companies, SanBio Co., Ltd., and SanBio, Inc.) 1. Details of the Decision As part of its mission to introduce new therapeutic drugs for the central nervous system,

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 02:05

Design of a randomized trial testing a multi-level weight-control intervention to reduce obesity and related health conditions in low-income workers

Publication date: Available online 19 January 2019Source: Contemporary Clinical TrialsAuthor(s): Richard I. Stein, Jaime R. Strickland, Rachel G. Tabak, Ann Marie Dale, Graham A. Colditz, Bradley A. EvanoffAbstractWeight-control is a major public health focus for preventing multiple obesity-related health conditions. While clinic-based intensive lifestyle interventions are successful, low-socioeconomic-status (SES) populations, which have a higher burden of obesity, are difficult to reach; thus,...

ScienceDirect Publication: Contemporary Clinical Trials

Sun Jan 20, 2019 13:44